

Adrian F Hernandez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8802617/publications.pdf>

Version: 2024-02-01

871
papers

55,389
citations

1294

109
h-index

2323

199
g-index

951
all docs

951
docs citations

951
times ranked

38088
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 1228-1239.	13.9	1,455
2	Diuretic Strategies in Patients with Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2011, 364, 797-805.	13.9	1,363
3	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. <i>Lancet</i> , 2018, 392, 1519-1529.	6.3	1,179
4	Effect of Nesiritide in Patients with Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2011, 365, 32-43.	13.9	1,133
5	Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1268.	3.8	976
6	Relationship Between Early Physician Follow-up and 30-Day Readmission Among Medicare Beneficiaries Hospitalized for Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1716.	3.8	852
7	Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome. <i>New England Journal of Medicine</i> , 2012, 367, 2296-2304.	13.9	790
8	Medical Therapy for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 351-366.	1.2	775
9	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2022, 79, e263-e421.	1.2	774
10	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2022, 145, 101161CIR0000000000001063.	1.6	756
11	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2020, 382, 1883-1893.	13.9	753
12	Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction. <i>Circulation</i> , 2012, 126, 65-75.	1.6	681
13	Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2476-2486.	1.2	671
14	Time to Treatment With Intravenous Tissue Plasminogen Activator and Outcome From Acute Ischemic Stroke. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 2480.	3.8	662
15	Timeliness of Tissue-Type Plasminogen Activator Therapy in Acute Ischemic Stroke. <i>Circulation</i> , 2011, 123, 750-758.	1.6	510
16	2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1342-1433.	0.8	503
17	Incidence and Prevalence of Atrial Fibrillation and Associated Mortality Among Medicare Beneficiaries: 1993-2007. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 85-93.	0.9	476
18	Door-to-Needle Times for Tissue Plasminogen Activator Administration and Clinical Outcomes in Acute Ischemic Stroke Before and After a Quality Improvement Initiative. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 1632.	3.8	469

#	ARTICLE	IF	CITATIONS
19	Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 500.	3.8	457
20	Sex Differences in Medical Care and Early Death After Acute Myocardial Infarction. <i>Circulation</i> , 2008, 118, 2803-2810.	1.6	455
21	Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 105-113.	5.5	451
22	Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2533.	3.8	410
23	A Validated Risk Score for In-Hospital Mortality in Patients With Heart Failure From the American Heart Association Get With the Guidelines Program. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 25-32.	0.9	400
24	Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , 2016, 375, 534-544.	13.9	379
25	Sex and Racial Differences in the Use of Implantable Cardioverter-Defibrillators Among Patients Hospitalized With Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 1525-32.	3.8	365
26	ACCF 2012 Expert Consensus Document on Practical Clinical Considerations in the Interpretation of Troponin Elevations. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2427-2463.	1.2	352
27	Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure. <i>JAMA Cardiology</i> , 2018, 3, 44.	3.0	346
28	Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. <i>American Heart Journal</i> , 2009, 157, 995-1000.	1.2	344
29	Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1958.	3.8	329
30	Titration of Medical Therapy for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2365-2383.	1.2	327
31	Combination of Loop Diuretics With Thiazide-Type Diuretics in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1527-1534.	1.2	323
32	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1757-1780.	1.2	314
33	Improving Door-to-Needle Times in Acute Ischemic Stroke. <i>Stroke</i> , 2011, 42, 2983-2989.	1.0	313
34	Biomarker-guided therapy in chronic heart failure: A meta-analysis of randomized controlled trials. <i>American Heart Journal</i> , 2009, 158, 422-430.	1.2	303
35	Characteristics, Performance Measures, and In-Hospital Outcomes of the First One Million Stroke and Transient Ischemic Attack Admissions in Get With The Guidelines-Stroke. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 291-302.	0.9	296
36	Clinical Effectiveness of Beta-Blockers in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2009, 53, 184-192.	1.2	295

#	ARTICLE	IF	CITATIONS
37	Incidence and Prevalence of Heart Failure in Elderly Persons, 1994-2003. Archives of Internal Medicine, 2008, 168, 418.	4.3	290
38	Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. American Heart Journal, 2014, 168, 721-730.e3.	1.2	289
39	Systematic Review of the Incidence of Sudden Cardiac Death in the United States. Journal of the American College of Cardiology, 2011, 57, 794-801.	1.2	287
40	Advanced (Stage D) Heart Failure: A Statement From the Heart Failure Society of America Guidelines Committee. Journal of Cardiac Failure, 2015, 21, 519-534.	0.7	283
41	Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines. American Heart Journal, 2009, 157, 111-117.e2.	1.2	270
42	Impact of Heart Failure on Patients Undergoing Major Noncardiac Surgery. Anesthesiology, 2008, 108, 559-567.	1.3	265
43	Prediction of 30-Day All-Cause Readmissions in Patients Hospitalized for Heart Failure. JAMA Cardiology, 2017, 2, 204.	3.0	249
44	Sex Differences in the Use of Implantable Cardioverter-Defibrillators for Primary and Secondary Prevention of Sudden Cardiac Death. JAMA - Journal of the American Medical Association, 2007, 298, 1517-24.	3.8	247
45	Cardiohepatic Interactions in Heart Failure. Journal of the American College of Cardiology, 2013, 61, 2397-2405.	1.2	240
46	Mechanisms of Bleeding and Approach to Patients With Axial-Flow Left Ventricular Assist Devices. Circulation: Heart Failure, 2011, 4, 779-784.	1.6	239
47	Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients. Circulation, 2015, 131, 1763-1771.	1.6	239
48	Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury. Circulation, 2018, 137, 2016-2028.	1.6	239
49	Predictors of Cardiac Rehabilitation Referral in Coronary Artery Disease Patients. Journal of the American College of Cardiology, 2009, 54, 515-521.	1.2	236
50	Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure. Circulation: Heart Failure, 2015, 8, 741-748.	1.6	235
51	Heart failure drug treatment. Lancet, The, 2019, 393, 1034-1044.	6.3	233
52	Risk Score for In-Hospital Ischemic Stroke Mortality Derived and Validated Within the Get With The Guidelinesâ€“Stroke Program. Circulation, 2010, 122, 1496-1504.	1.6	232
53	Use of Aldosterone Antagonists in Heart Failure. JAMA - Journal of the American Medical Association, 2009, 302, 1658.	3.8	231
54	Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice. American Heart Journal, 2014, 167, 846-852.e2.	1.2	218

#	ARTICLE	IF	CITATIONS
55	Non-“Evidence-Based ICD Implantations in the United States. JAMA - Journal of the American Medical Association, 2011, 305, 43.	3.8	207
56	Transitions of Care in Heart Failure. Circulation: Heart Failure, 2015, 8, 384-409.	1.6	206
57	Admission, Discharge, or Change in B-Type Natriuretic Peptide and Long-Term Outcomes. Circulation: Heart Failure, 2011, 4, 628-636.	1.6	199
58	Efficacy and Safety of Spironolactone in Acute Heart Failure. JAMA Cardiology, 2017, 2, 950.	3.0	199
59	Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. American Heart Journal, 2011, 161, 1024-1030.e3.	1.2	196
60	Risk Score for Intracranial Hemorrhage in Patients With Acute Ischemic Stroke Treated With Intravenous Tissue-Type Plasminogen Activator. Stroke, 2012, 43, 2293-2299.	1.0	196
61	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the <scp>DELIVER</scp> trial. European Journal of Heart Failure, 2021, 23, 1217-1225.	2.9	195
62	Emergency Medical Service Hospital Prenotification Is Associated With Improved Evaluation and Treatment of Acute Ischemic Stroke. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 514-522.	0.9	192
63	Outcomes in Mild or Rapidly Improving Stroke Not Treated With Intravenous Recombinant Tissue-Type Plasminogen Activator. Stroke, 2011, 42, 3110-3115.	1.0	187
64	Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2018, 320, 1764.	3.8	187
65	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. European Journal of Heart Failure, 2013, 15, 1082-1094.	2.9	182
66	Heart Failure With Preserved Ejection Fraction and Diabetes. Journal of the American College of Cardiology, 2019, 73, 602-611.	1.2	182
67	Outcomes in heart failure patients after major noncardiac surgery. Journal of the American College of Cardiology, 2004, 44, 1446-1453.	1.2	180
68	Association of Intracerebral Hemorrhage Among Patients Taking Non-“Vitamin K Antagonist vs Vitamin K Antagonist Oral Anticoagulants With In-Hospital Mortality. JAMA - Journal of the American Medical Association, 2018, 319, 463.	3.8	180
69	Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. JACC: Heart Failure, 2016, 4, 464-472.	1.9	179
70	Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. JAMA - Journal of the American Medical Association, 2017, 317, 1057.	3.8	179
71	Comparative Risk for Angioedema Associated With the Use of Drugs That Target the Renin-Angiotensin-Aldosterone System. Archives of Internal Medicine, 2012, 172, 1582.	4.3	178
72	Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. Journal of the American Heart Association, 2016, 5, .	1.6	178

#	ARTICLE	IF	CITATIONS
73	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1512.	3.8	170
74	Discharge to a Skilled Nursing Facility and Subsequent Clinical Outcomes Among Older Patients Hospitalized for Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 293-300.	1.6	165
75	Cardiovascular Phenotype in HFpEF Patients With or Without Diabetes. <i>Journal of the American College of Cardiology</i> , 2014, 64, 541-549.	1.2	157
76	Patient Characteristics From a Regional Multicenter Database of Acute Decompensated Heart Failure in Asia Pacific (ADHERE Internationalâ€“Asia Pacific). <i>Journal of Cardiac Failure</i> , 2012, 18, 82-88.	0.7	155
77	Early and Long-term Outcomes of Heart Failure in Elderly Persons, 2001-2005. <i>Archives of Internal Medicine</i> , 2008, 168, 2481.	4.3	154
78	Comparison of 30-Day Mortality Models for Profiling Hospital Performance in Acute Ischemic Stroke With vs Without Adjustment for Stroke Severity. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 257-64.	3.8	153
79	Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. <i>European Heart Journal</i> , 2014, 35, 250-256.	1.0	148
80	Markers of Decongestion, Dyspnea Relief, and Clinical Outcomes Among Patients Hospitalized With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2013, 6, 240-245.	1.6	147
81	Resource Use in the Last 6 Months of Life Among Medicare Beneficiaries With Heart Failure, 2000-2007. <i>Archives of Internal Medicine</i> , 2011, 171, 196.	4.3	146
82	Data quality in the American Heart Association Get With The Guidelines-Stroke (GWTG-Stroke): Results from a National Data Validation Audit. <i>American Heart Journal</i> , 2012, 163, 392-398.e1.	1.2	145
83	Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2021, 384, 1981-1990.	13.9	145
84	Patterns of Emergency Medical Services Use and Its Association With Timely Stroke Treatment. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 262-269.	0.9	144
85	Risks of Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Receiving Warfarin and Treated With Intravenous Tissue Plasminogen Activator. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 2600-8.	3.8	142
86	Temporal Trends and Factors Associated With Cardiac Rehabilitation Referral Among Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2015, 66, 917-926.	1.2	142
87	Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). <i>American Heart Journal</i> , 2009, 157, 271-277.	1.2	141
88	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator. <i>JACC: Heart Failure</i> , 2018, 6, 96-104.	1.9	141
89	Outcomes of Medicare Beneficiaries Undergoing Catheter Ablation for Atrial Fibrillation. <i>Circulation</i> , 2012, 126, 2200-2207.	1.6	138
90	Racial and Ethnic Differences in the Treatment of Acute Myocardial Infarction. <i>Circulation</i> , 2010, 121, 2294-2301.	1.6	137

#	ARTICLE	IF	CITATIONS
91	Times From Symptom Onset to Hospital Arrival in the Get With The Guidelines“Stroke Program 2002 to 2009. <i>Stroke</i> , 2012, 43, 1912-1917.	1.0	136
92	Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes. <i>Circulation: Heart Failure</i> , 2010, 3, 314-325.	1.6	134
93	Impact of Atrial Fibrillation on Exercise Capacity in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 123-130.	1.6	134
94	Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure. <i>Circulation: Heart Failure</i> , 2018, 11, e004646.	1.6	134
95	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2022, 145, 101161CIR0000000000001062.	1.6	133
96	Medical Therapies and Invasive Treatments for Coronary Artery Disease by Body Mass: The “Obesity Paradox” in the Get With The Guidelines Database. <i>American Journal of Cardiology</i> , 2007, 100, 1331-1335.	0.7	130
97	Quality of Care for Atrial Fibrillation Among Patients Hospitalized for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1280-1289.	1.2	129
98	Treatment With Tissue Plasminogen Activator in the Golden Hour and the Shape of the 4.5-Hour Time-Benefit Curve in the National United States Get With The Guidelines-Stroke Population. <i>Circulation</i> , 2017, 135, 128-139.	1.6	129
99	Age and Gender Differences in Quality of Care and Outcomes for Patients with ST-segment Elevation Myocardial Infarction. <i>American Journal of Medicine</i> , 2012, 125, 1000-1009.	0.6	128
100	Role of Volume Redistribution in the Congestion of Heart Failure. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	128
101	Trends in 30-Day Readmission Rates for Patients Hospitalized With Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	127
102	Pragmatic clinical trials embedded in healthcare systems: generalizable lessons from the NIH Collaboratory. <i>BMC Medical Research Methodology</i> , 2017, 17, 144.	1.4	127
103	Associations Between Aldosterone Antagonist Therapy and Risks of Mortality and Readmission Among Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 2097.	3.8	125
104	Off-Hour Admission and In-Hospital Stroke Case Fatality in the Get With The Guidelines-Stroke Program. <i>Stroke</i> , 2009, 40, 569-576.	1.0	124
105	Trends in Use of Implantable Cardioverter-Defibrillator Therapy Among Patients Hospitalized for Heart Failure. <i>Circulation</i> , 2012, 125, 1094-1101.	1.6	124
106	Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the <sc>RELAX</sc> trial. <i>European Journal of Heart Failure</i> , 2017, 19, 893-900.	2.9	123
107	Hospital Variation and Characteristics of Implantable Cardioverter-Defibrillator Use in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2009, 53, 416-422.	1.2	120
108	Hospital-Level Variation in Mortality and Rehospitalization for Medicare Beneficiaries With Acute Ischemic Stroke. <i>Stroke</i> , 2011, 42, 159-166.	1.0	120

#	ARTICLE	IF	CITATIONS
109	Utility of Patient-Reported Outcome Instruments in Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 165-175.	1.9	120
110	Relationship of National Institutes of Health Stroke Scale to 30-Day Mortality in Medicare Beneficiaries With Acute Ischemic Stroke. <i>Journal of the American Heart Association</i> , 2012, 1, 42-50.	1.6	116
111	Get With The Guidelines Program Participation, Process of Care, and Outcome for Medicare Patients Hospitalized With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 37-43.	0.9	115
112	Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry. <i>American Heart Journal</i> , 2016, 182, 9-20.	1.2	115
113	Generalizability and longitudinal outcomes of a national heart failure clinical registry: Comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and non-ADHERE Medicare beneficiaries. <i>American Heart Journal</i> , 2010, 160, 885-892.	1.2	114
114	Diuretic response in acute heart failure—an analysis from ASCEND-HF. <i>American Heart Journal</i> , 2015, 170, 313-321.e4.	1.2	110
115	Representativeness of the Get With The Guidelines-Stroke Registry. <i>Stroke</i> , 2012, 43, 44-49.	1.0	108
116	Primary graft dysfunction after heart transplantation: Incidence, trends, and associated risk factors. <i>American Journal of Transplantation</i> , 2018, 18, 1461-1470.	2.6	108
117	Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure (RELAX) Trial. <i>Circulation: Heart Failure</i> , 2012, 5, 653-659.	1.6	107
118	2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012, 144, e29-e84.	0.4	107
119	Presence of Atrial Fibrillation Is Independently Associated With Adverse Outcomes in Patients Hospitalized With Heart Failure. <i>Circulation: Heart Failure</i> , 2012, 5, 191-201.	1.6	106
120	Synthesizing Lessons Learned From Get With The Guidelines. <i>Circulation</i> , 2013, 128, 2447-2460.	1.6	106
121	Management of Postoperative Atrial Fibrillation and Subsequent Outcomes in Contemporary Patients Undergoing Cardiac Surgery: Insights From the Society of Thoracic Surgeons CAPS Care Atrial Fibrillation Registry. <i>Clinical Cardiology</i> , 2014, 37, 7-13.	0.7	105
122	Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	104
123	Do Countries or Hospitals With Longer Hospital Stays for Acute Heart Failure Have Lower Readmission Rates?. <i>Circulation: Heart Failure</i> , 2013, 6, 727-732.	1.6	103
124	Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. <i>European Journal of Heart Failure</i> , 2012, 14, 1257-1264.	2.9	101
125	Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 305-309.	1.9	101
126	The Future of Wearables in Heart Failure Patients. <i>JACC: Heart Failure</i> , 2019, 7, 922-932.	1.9	101

#	ARTICLE	IF	CITATIONS
127	Patient and Implanting Physician Factors Associated With Mortality and Complications After Implantable Cardioverter-Defibrillator Implantation, 2002-2005. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2008, 1, 240-249.	2.1	99
128	PCORnet® 2020: current state, accomplishments, and future directions. <i>Journal of Clinical Epidemiology</i> , 2021, 129, 60-67.	2.4	98
129	National Survey of Hospital Strategies to Reduce Heart Failure Readmissions. <i>Circulation: Heart Failure</i> , 2012, 5, 680-687.	1.6	97
130	Characteristics and in-hospital outcomes for nonadherent patients with heart failure: Findings from Get With The Guidelines-Heart Failure (GWTG-HF). <i>American Heart Journal</i> , 2009, 158, 644-652.	1.2	96
131	Incremental Value of Clinical Data Beyond Claims Data in Predicting 30-Day Outcomes After Heart Failure Hospitalization. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 60-67.	0.9	96
132	Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. <i>American Heart Journal</i> , 2012, 164, 763-770.e3.	1.2	95
133	Validated, Electronic Health Record Deployable Prediction Models for Assessing Patient Risk of 30-Day Rehospitalization and Mortality in Older Heart Failure Patients. <i>JACC: Heart Failure</i> , 2013, 1, 245-251.	1.9	95
134	Decongestion Strategies and Renin-Angiotensin-Aldosterone System Activation in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 97-107.	1.9	95
135	A Decade of Short-Term Outcomes in Post-Cardiac Surgery Ventricular Assist Device Implantation. <i>Circulation</i> , 2007, 116, 606-612.	1.6	94
136	The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. <i>TH Open</i> , 2017, 01, e56-e65.	0.7	94
137	Indications for Cardiac Resynchronization Therapy: 2011 Update From the Heart Failure Society of America Guideline Committee. <i>Journal of Cardiac Failure</i> , 2012, 18, 94-106.	0.7	93
138	End Points for Clinical Trials in Acute Heart Failure Syndromes. <i>Journal of the American College of Cardiology</i> , 2009, 53, 2248-2258.	1.2	92
139	The ADAPTABLE Trial and PCORnet: Shining Light on a New Research Paradigm. <i>Annals of Internal Medicine</i> , 2015, 163, 635-636.	2.0	91
140	Recurrence of Cardiac Sarcoidosis in a Heart Transplant Recipient. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 1988-1990.	0.3	90
141	Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure. <i>Circulation</i> , 2016, 134, 517-526.	1.6	90
142	Use of Cardiac Resynchronization Therapy in Patients Hospitalized With Heart Failure. <i>Circulation</i> , 2008, 118, 926-933.	1.6	89
143	Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction. <i>American Heart Journal</i> , 2012, 163, 430-437.e3.	1.2	89
144	Post-discharge Follow-up Characteristics Associated With 30-Day Readmission After Heart Failure Hospitalization. <i>Medical Care</i> , 2016, 54, 365-372.	1.1	89

#	ARTICLE	IF	CITATIONS
145	Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure. <i>JAMA Cardiology</i> , 2016, 1, 714.	3.0	89
146	CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis. <i>Canadian Journal of Cardiology</i> , 2020, 36, 159-169.	0.8	89
147	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes. <i>JACC: Heart Failure</i> , 2020, 8, 931-939.	1.9	88
148	QRS Duration, Bundle-Branch Block Morphology, and Outcomes Among Older Patients With Heart Failure Receiving Cardiac Resynchronization Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 617.	3.8	86
149	Process of Care Performance Measures and Long-Term Outcomes in Patients Hospitalized With Heart Failure. <i>Medical Care</i> , 2010, 48, 210-216.	1.1	85
150	Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes. <i>JACC: Heart Failure</i> , 2017, 5, 1-13.	1.9	84
151	Association of race/ethnicity with clinical risk factors, quality of care, and acute outcomes in patients hospitalized with heart failure. <i>American Heart Journal</i> , 2011, 161, 746-754.	1.2	83
152	Representativeness of a National Heart Failure Quality-of-Care Registry. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 377-384.	0.9	82
153	Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial. <i>American Heart Journal</i> , 2016, 174, 103-110.	1.2	82
154	Use of Strategies to Improve Door-to-Needle Times With Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	82
155	The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. <i>American Heart Journal</i> , 2014, 167, 335-341.	1.2	81
156	Strategies Used by Hospitals to Improve Speed of Tissue-Type Plasminogen Activator Treatment in Acute Ischemic Stroke. <i>Stroke</i> , 2014, 45, 1387-1395.	1.0	81
157	Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures. <i>Circulation</i> , 2015, 132, 1347-1353.	1.6	81
158	Good Clinical Practice Guidance and Pragmatic Clinical Trials. <i>Circulation</i> , 2016, 133, 872-880.	1.6	79
159	Effects of Nesiritide and Predictors of Urine Output in Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1177-1183.	1.2	78
160	Prospective and External Evaluation of a Machine Learning Model to Predict In-Hospital Mortality of Adults at Time of Admission. <i>JAMA Network Open</i> , 2020, 3, e1920733.	2.8	78
161	Achieving rapid reperfusion with primary percutaneous coronary intervention remains a challenge: Insights from American Heart Association's Get With the Guidelines program. <i>American Heart Journal</i> , 2008, 155, 1059-1067.	1.2	77
162	Left Ventricular Assist Device Destination Therapy Versus Extended Criteria Cardiac Transplant. <i>Annals of Thoracic Surgery</i> , 2010, 89, 1205-1210.	0.7	77

#	ARTICLE	IF	CITATIONS
163	Outcomes With an Alternate List Strategy for Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, 1781-1786.	0.3	75
164	Long-term Outcomes and Costs of Ventricular Assist Devices Among Medicare Beneficiaries. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 2398.	3.8	75
165	d-Dimer elevation and adverse outcomes. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 55-59.	1.0	75
166	The Changing Landscape of Randomized Clinical Trials in Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1898-1907.	1.2	75
167	Trends in Readmissions and Length of Stay for Patients Hospitalized With Heart Failure in Canada and the United States. <i>JAMA Cardiology</i> , 2019, 4, 444.	3.0	75
168	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 184-197.	1.9	75
169	Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. <i>American Heart Journal</i> , 2013, 165, 979-986.e1.	1.2	74
170	Trends in the Use of Evidence-Based Treatments for Coronary Artery Disease Among Women and the Elderly. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2009, 2, 633-641.	0.9	73
171	Weekend hospital admission and discharge for heart failure: Association with quality of care and clinical outcomes. <i>American Heart Journal</i> , 2009, 158, 451-458.	1.2	73
172	Predictors of Hospital Length of Stay in Heart Failure: Findings from Get With the Guidelines. <i>Journal of Cardiac Failure</i> , 2011, 17, 649-656.	0.7	73
173	A Risk Score for In-Hospital Death in Patients Admitted With Ischemic or Hemorrhagic Stroke. <i>Journal of the American Heart Association</i> , 2013, 2, e005207.	1.6	73
174	Treatment and Risk in Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2010, 3, 309-315.	0.9	72
175	Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure. <i>Circulation: Heart Failure</i> , 2010, 3, 7-13.	1.6	72
176	Home-Time After Discharge Among Patients Hospitalized With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2643-2652.	1.2	72
177	Quality of care and outcomes among patients with heart failure and chronic kidney disease: A Get With the Guidelines [®] Heart Failure Program study. <i>American Heart Journal</i> , 2008, 156, 674-681.	1.2	71
178	Effects of Left Ventricular Assist Device Support on Biomarkers of Cardiovascular Stress, Fibrosis, Fluid Homeostasis, Inflammation, and Renal Injury. <i>JACC: Heart Failure</i> , 2015, 3, 30-39.	1.9	70
179	Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke. <i>JAMA Neurology</i> , 2019, 76, 1192.	4.5	70
180	Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 3029-3039.	1.2	69

#	ARTICLE	IF	CITATIONS
181	Association of Patient Case-Mix Adjustment, Hospital Process Performance Rankings, and Eligibility for Financial Incentives. JAMA - Journal of the American Medical Association, 2008, 300, 1897.	3.8	68
182	Quality of Care for Acute Coronary Syndrome Patients With Known Atherosclerotic Disease. Circulation, 2009, 120, 560-567.	1.6	68
183	Association of 30-Day Readmission Metric for Heart Failure Under the Hospital Readmissions Reduction Program With Quality of Care and Outcomes. JACC: Heart Failure, 2016, 4, 935-946.	1.9	68
184	Rhythm Control Versus Rate Control in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction: Insights From Get With The Guidelines Heart Failure. Journal of the American Heart Association, 2019, 8, e011560.	1.6	68
185	Cardiopulmonary Impact of Particulate Air Pollution in High-Risk Populations. Journal of the American College of Cardiology, 2020, 76, 2878-2894.	1.2	68
186	Effect of a Hospital and Postdischarge Quality Improvement Intervention on Clinical Outcomes and Quality of Care for Patients With Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2021, 326, 314.	3.8	68
187	Patterns and Predictors of Evidence-Based Medication Continuation Among Hospitalized Heart Failure Patients (from Get With the Guidelines Heart Failure). American Journal of Cardiology, 2011, 107, 1818-1823.	0.7	67
188	Racial and Ethnic Differences in Outcomes in Older Patients With Acute Ischemic Stroke. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 284-292.	0.9	67
189	Short- and Long-term Rehospitalization and Mortality for Heart Failure in 4 Racial/Ethnic Populations. Journal of the American Heart Association, 2014, 3, e001134.	1.6	67
190	Assessment of Home-Time After Acute Ischemic Stroke in Medicare Beneficiaries. Stroke, 2016, 47, 836-842.	1.0	67
191	Target Doses of Heart Failure Medical Therapy and Blood Pressure. JACC: Heart Failure, 2019, 7, 350-358.	1.9	67
192	Long-Term Outcomes of Medicare Beneficiaries With Worsening Renal Function During Hospitalization for Heart Failure. American Journal of Cardiology, 2010, 105, 1786-1793.	0.7	66
193	Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure. JACC: Heart Failure, 2018, 6, 465-473.	1.9	65
194	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq0 0 0 rgBT /Qverlock 10 Tf 50 222	2.9	65
195	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 2109-2117.	1.0	65
196	Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease. JAMA - Journal of the American Medical Association, 2021, 325, 39.	3.8	65
197	Door-to-Balloon Times in Hospitals Within the Get-With-The-Guidelines Registry After Initiation of the Door-to-Balloon (D2B) Alliance. American Journal of Cardiology, 2009, 103, 1051-1055.	0.7	63
198	Microvascular and Cardiovascular Outcomes According to Renal Function in Patients Treated With Once-Weekly Exenatide: Insights From the EXSCEL Trial. Diabetes Care, 2020, 43, 446-452.	4.3	63

#	ARTICLE	IF	CITATIONS
199	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure. <i>Circulation</i> , 2020, 142, 1205-1218.	1.6	63
200	Current Use of Beta Blockers in Patients With Reactive Airway Disease Who Are Hospitalized With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2009, 103, 295-300.	0.7	62
201	A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. <i>Kidney International</i> , 2010, 77, 239-246.	2.6	62
202	The Need for Multiple Measures of Hospital Quality. <i>Circulation</i> , 2011, 124, 712-719.	1.6	62
203	Trends in Endovascular Therapy and Clinical Outcomes Within the Nationwide Get With The Guidelines-Stroke Registry. <i>Stroke</i> , 2015, 46, 989-995.	1.0	62
204	Diabetes and long-term outcomes of ischaemic stroke: findings from Get With The Guidelines-Stroke. <i>European Heart Journal</i> , 2018, 39, 2376-2386.	1.0	62
205	Splanchnic Nerve Block for Acute Heart Failure. <i>Circulation</i> , 2018, 138, 951-953.	1.6	62
206	Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 522.	3.0	62
207	Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. <i>American Heart Journal</i> , 2008, 156, 1170-1176.	1.2	61
208	Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients. <i>Circulation</i> , 2017, 135, 648-655.	1.6	61
209	Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry. <i>European Journal of Heart Failure</i> , 2011, 13, 945-952.	2.9	60
210	Valvular Heart Disease in Patients Supported With Left Ventricular Assist Devices. <i>Circulation: Heart Failure</i> , 2014, 7, 215-222.	1.6	60
211	Heart Rate at Hospital Discharge in Patients With Heart Failure Is Associated With Mortality and Rehospitalization. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	60
212	Rationale and design of the comparison Of sacubitril/valsartan versus Enalapril on Effect on natriuretic peptide (PIONEER-HF) trial. <i>American Heart Journal</i> , 2018, 198, 145-151.	1.2	60
213	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI Cardiovascular Medical Research and Education Fund Workshop Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1661-1670.	2.5	59
214	Rationale and Design of the Aspirin Dosing—A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. <i>JAMA Cardiology</i> , 2020, 5, 598.	3.0	59
215	Influence of age on the management of heart failure: Findings from Get With the Guidelines—Heart Failure (GWTC-HF). <i>American Heart Journal</i> , 2009, 157, 1010-1017.	1.2	58
216	A review of dyspnea in acute heart failure syndromes. <i>American Heart Journal</i> , 2010, 160, 209-214.	1.2	58

#	ARTICLE	IF	CITATIONS
217	Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. <i>Hepatology</i> , 2015, 62, 409-416.	3.6	58
218	Seasonal and circadian variations of acute myocardial infarction: Findings from the Get With The Guidelinesâ€“Coronary Artery Disease (GWTG-CAD) program. <i>American Heart Journal</i> , 2017, 189, 85-93.	1.2	58
219	Renal Dysfunction Is Associated With Poststroke Discharge Disposition and In-Hospital Mortality. <i>Stroke</i> , 2017, 48, 327-334.	1.0	58
220	Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failureâ€“Related Outcomes. <i>Circulation</i> , 2019, 140, 1613-1622.	1.6	58
221	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the <sc>VICTORIA</sc> (<sc>Vericiguat</sc> Global Study in) Tj ETQq1 1 0.7849 14 rgB34 Overlock	1.0	58
222	High-Sensitivity C-Reactive Protein in Acute Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2014, 20, 319-326.	0.7	57
223	Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction. <i>American Heart Journal</i> , 2014, 167, 369-375.e2.	1.2	57
224	Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. <i>American Heart Journal</i> , 2015, 170, 290-297.e1.	1.2	57
225	Sex and Race/Ethnicityâ€“Related Disparities in Care and Outcomes After Hospitalization for Coronary Artery Disease Among Older Adults. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, S36-44.	0.9	57
226	The Hospital Readmissions Reduction Program. <i>JACC: Heart Failure</i> , 2020, 8, 1-11.	1.9	57
227	Relationships between emerging measures of heart failure processes of care and clinical outcomes. <i>American Heart Journal</i> , 2010, 159, 406-413.	1.2	56
228	Exercise Training and Implantable Cardioverter-Defibrillator Shocks in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 142-148.	1.9	56
229	The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the <sc>ASCENDâ€“HF T</sc>rial. <i>European Journal of Heart Failure</i> , 2014, 16, 334-341.	2.9	56
230	Effect of Serelaxin on Mode of Death inâ€“Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1591-1598.	1.2	56
231	Trends in the Use and Outcomes of Ventricular Assistâ€“Devices Among Medicareâ€“Beneficiaries, 2006â€“Through 2011. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1395-1404.	1.2	56
232	Combined neprilysin and reninâ€“angiotensin system inhibition in heart failure with reduced ejection fraction: a metaâ€“analysis. <i>European Journal of Heart Failure</i> , 2016, 18, 1238-1243.	2.9	56
233	Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with in-hospital outcomes: Findings from the Get With The Guidelineâ€“Heart Failure Registry. <i>American Heart Journal</i> , 2013, 166, 1063-1071.e3.	1.2	55
234	Thrombolytic Therapy for Thrombosis of Continuous Flow Ventricular Assist Devices. <i>Journal of Cardiac Failure</i> , 2014, 20, 91-97.	0.7	55

#	ARTICLE	IF	CITATIONS
235	Utility of Socioeconomic Status in Predicting 30-Day Outcomes After Heart Failure Hospitalization. <i>Circulation: Heart Failure</i> , 2015, 8, 473-480.	1.6	55
236	Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation. <i>American Heart Journal</i> , 2013, 165, 567-574.e6.	1.2	54
237	Real world effectiveness of warfarin among ischemic stroke patients with atrial fibrillation: observational analysis from Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study. <i>BMJ, The</i> , 2015, 351, h3786.	3.0	54
238	Characteristics, Treatments, and Outcomes of Hospitalized Heart Failure Patients Stratified by Etiologies of Cardiomyopathy. <i>JACC: Heart Failure</i> , 2015, 3, 906-916.	1.9	54
239	QEEG Spectral and Coherence Assessment of Autistic Children in Three Different Experimental Conditions. <i>Journal of Autism and Developmental Disorders</i> , 2015, 45, 406-424.	1.7	54
240	The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. <i>Current Cardiology Reports</i> , 2016, 18, 81.	1.3	54
241	Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator. <i>JAMA Neurology</i> , 2016, 73, 50.	4.5	54
242	An Initial Evaluation of the Impact of PokÃ©mon GO on Physical Activity. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	54
243	Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF. <i>European Heart Journal</i> , 2018, 39, 4255-4256.	1.0	54
244	Defining Heart Failure End Points in ST-Segment Elevation Myocardial Infarction Trials. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 594-600.	0.9	53
245	Acute Decompensated Heart Failure: Update on New and Emerging Evidence and Directions for Future Research. <i>Journal of Cardiac Failure</i> , 2013, 19, 371-389.	0.7	53
246	Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1973.	3.8	53
247	Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event. <i>JAMA Cardiology</i> , 2021, 6, 706.	3.0	53
248	Outcomes of Medicare Beneficiaries With Heart Failure and Atrial Fibrillation. <i>JACC: Heart Failure</i> , 2014, 2, 41-48.	1.9	52
249	Novel Oral Anticoagulant Use Among Patients With Atrial Fibrillation Hospitalized With Ischemic Stroke or Transient Ischemic Attack. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 383-392.	0.9	52
250	Association of Get With The Guidelines-Stroke Program Participation and Clinical Outcomes for Medicare Beneficiaries With Ischemic Stroke. <i>Stroke</i> , 2016, 47, 1294-1302.	1.0	52
251	How Medicine Has Changed the End of Life for Patients With Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1276-1289.	1.2	52
252	Generating comparative evidence on new drugs and devices after approval. <i>Lancet, The</i> , 2020, 395, 998-1010.	6.3	52

#	ARTICLE	IF	CITATIONS
253	Impact of the Early Phase of the COVID-19 Pandemic on US Healthcare Workers: Results from the HERO Registry. <i>Journal of General Internal Medicine</i> , 2021, 36, 1319-1326.	1.3	52
254	Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitusâ€”Rationale, design, and baseline characteristics. <i>American Heart Journal</i> , 2018, 203, 30-38.	1.2	51
255	Device Therapy in Heart Failure Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2011, 58, 889-896.	1.2	50
256	Update on Aldosterone Antagonists Use in Heart Failure With Reduced Left Ventricular Ejection Fraction Heart Failure Society of America Guidelines Committee. <i>Journal of Cardiac Failure</i> , 2012, 18, 265-281.	0.7	50
257	Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2017, 2, 136.	3.0	50
258	Trends in Hospice Discharge and Relative Outcomes Among Medicare Patients in the Get With The Guidelinesâ€”Heart Failure Registry. <i>JAMA Cardiology</i> , 2018, 3, 917.	3.0	50
259	Inverse relationship of serum albumin to the risk of venous thromboembolism among acutely ill hospitalized patients: Analysis from the APEX trial. <i>American Journal of Hematology</i> , 2019, 94, 21-28.	2.0	50
260	Randomized Trials Versus Common Sense and Clinical Observation. <i>Journal of the American College of Cardiology</i> , 2020, 76, 580-589.	1.2	50
261	Early intravenous heart failure therapy and outcomes among older patients hospitalized for acute decompensated heart failure: Findings from the Acute Decompensated Heart Failure Registry Emergency Module (ADHERE-EM). <i>American Heart Journal</i> , 2013, 166, 349-356.	1.2	49
262	Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research: Implementing the patient-driven research paradigm to aid decision making in stroke care. <i>American Heart Journal</i> , 2015, 170, 36-45.e11.	1.2	49
263	Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>American Heart Journal</i> , 2017, 187, 1-9.	1.2	49
264	Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 202-210.	0.3	49
265	Return of Research Results to Study Participants. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 435.	3.8	49
266	Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group. <i>American Heart Journal</i> , 2009, 157, 957-970.	1.2	48
267	Care and Outcomes of Hispanic Patients Admitted With Heart Failure With Preserved or Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2012, 5, 167-175.	1.6	48
268	In-Hospital Worsening Heart Failure and Associations With Mortality, Readmission, and Healthcare Utilization. <i>Journal of the American Heart Association</i> , 2014, 3, .	1.6	48
269	Intensification of Medication Therapy for Cardiorenal Syndrome in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, 26-32.	0.7	48
270	Use of Intravenous Recombinant Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke Who Take Non-Vitamin K Antagonist Oral Anticoagulants Before Stroke. <i>Circulation</i> , 2017, 135, 1024-1035.	1.6	48

#	ARTICLE	IF	CITATIONS
271	The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous) Tj ETQq1 1 0.784314 rgBT /Overlo Journal, 2017, 185, 93-100.	1.2	48
272	Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. Thrombosis and Haemostasis, 2018, 118, 2046-2052.	1.8	48
273	Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCel trial. Cardiovascular Diabetology, 2019, 18, 138.	2.7	48
274	The Dissociation Between Door-to-Balloon Time Improvement and Improvements in Other Acute Myocardial Infarction Care Processes and Patient Outcomes. Archives of Internal Medicine, 2009, 169, 1411.	4.3	47
275	Payment Source, Quality of Care, and Outcomes in Patients Hospitalized With Heart Failure. Journal of the American College of Cardiology, 2011, 58, 1465-1471.	1.2	47
276	Targeting anti- β_1 -adrenergic receptor antibodies for dilated cardiomyopathy. European Journal of Heart Failure, 2013, 15, 724-729.	2.9	47
277	Predictors of Adherence to Performance Measures in Patients with Acute Myocardial Infarction. American Journal of Medicine, 2013, 126, 74.e1-74.e9.	0.6	47
278	Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. European Journal of Heart Failure, 2016, 18, 290-297.	2.9	47
279	Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). American Journal of Cardiology, 2016, 117, 404-411.	0.7	47
280	Can Vaccinations Improve Heart Failure Outcomes?. JACC: Heart Failure, 2017, 5, 194-203.	1.9	47
281	INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved) Tj ETQq1 1 0.784314 rgBT /Overlo Journal, 2017, 185, 93-100.	1.6	47
282	Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF. JACC: Heart Failure, 2020, 8, 469-480.	1.9	47
283	Quality of Care and Outcomes in Women Hospitalized for Heart Failure. Circulation: Heart Failure, 2011, 4, 589-598.	1.6	46
284	2012 ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement. Catheterization and Cardiovascular Interventions, 2012, 79, 1023-1082.	0.7	46
285	Are we targeting the right metric for heart failure? Comparison of hospital 30-day readmission rates and total episode of care inpatient days. American Heart Journal, 2013, 165, 987-994.e1.	1.2	46
286	Temporal Trends and Predictors in the Use of Aldosterone Antagonists Post-Acute Myocardial Infarction. Journal of the American College of Cardiology, 2013, 61, 35-40.	1.2	46
287	Has Public Reporting of Hospital Readmission Rates Affected Patient Outcomes?. Journal of the American College of Cardiology, 2016, 67, 963-972.	1.2	46
288	Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure. Circulation, 2018, 137, 1661-1670.	1.6	46

#	ARTICLE	IF	CITATIONS
289	Results of the Chronic Heart Failure Intervention to Improve MEducation Adherence study: A randomized intervention in high-risk patients. <i>American Heart Journal</i> , 2015, 169, 539-548.	1.2	45
290	Liver function tests in patients with acute heart failure and associated outcomes: insights from <sc>ASCENDâ€HF</sc>. <i>European Journal of Heart Failure</i> , 2016, 18, 424-432.	2.9	45
291	Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 68-77.	1.9	45
292	Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, e003878.	1.6	45
293	Dysphagia Screening and Hospital-acquired Pneumonia in Patients with Acute Ischemic Stroke: Findings from Get with the Guidelinesâ€Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2013, 22, e301-e309.	0.7	44
294	Relationship of Race/Ethnicity With Door-to-Balloon Time and Mortality in Patients Undergoing Primary Percutaneous Coronary Intervention for <sc>ST</sc>-Elevation Myocardial Infarction: Findings From Get With the Guidelinesâ€Coronary Artery Disease. <i>Clinical Cardiology</i> , 2013, 36, 749-756.	0.7	44
295	PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network. <i>Journal of the American Heart Association</i> , 2019, 8, e011246.	1.6	44
296	Splanchnic Nerve Block for Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 742-752.	1.9	44
297	Racial Differences in the Prevalence and Outcomes of Atrial Fibrillation Among Patients Hospitalized With Heart Failure. <i>Journal of the American Heart Association</i> , 2013, 2, e000200.	1.6	43
298	Clinical Effectiveness of Statin Therapy After Ischemic Stroke: Primary Results From the Statin Therapeutic Area of the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. <i>Circulation</i> , 2015, 132, 1404-1413.	1.6	43
299	Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry. <i>American Heart Journal</i> , 2017, 189, 177-183.	1.2	43
300	Sustained sex-based treatment differences in acute coronary syndrome care: Insights from the American Heart Association Get With The Guidelines Coronary Artery Disease Registry. <i>Clinical Cardiology</i> , 2018, 41, 758-768.	0.7	43
301	Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure With Reduced Ejection Fraction Patients. <i>JACC: Heart Failure</i> , 2021, 9, 28-38.	1.9	43
302	Changes in Myocardial Infarction Guideline Adherence as a Function of Patient Risk. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1760-1765.	1.2	42
303	Guideline Adherence After ST-Segment Elevation Versus Non-ST Segment Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2012, 5, 654-661.	0.9	42
304	Hypotension During Hospitalization for Acute Heart Failure Is Independently Associated With 30-Day Mortality. <i>Circulation: Heart Failure</i> , 2014, 7, 918-925.	1.6	42
305	Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCENDâ€HF. <i>European Journal of Heart Failure</i> , 2018, 20, 304-314.	2.9	42
306	Time for NIH to lead on data sharing. <i>Science</i> , 2020, 367, 1308-1309.	6.0	42

#	ARTICLE	IF	CITATIONS
307	Renal Outcomes in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes</i> , 2018, 67, .	0.3	42
308	2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary. <i>Journal of Cardiac Failure</i> , 2022, 28, 810-830.	0.7	42
309	Nesiritide, Renal Function, and Associated Outcomes During Hospitalization for Acute Decompensated Heart Failure. <i>Circulation</i> , 2014, 130, 958-965.	1.6	41
310	Peripheral Arterial Testing Before Lower Extremity Amputation Among Medicare Beneficiaries, 2000 to 2010. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 142-150.	0.9	41
311	GLP-1 Agonist Therapy for Advanced Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 673-679.	1.6	41
312	Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2017, 5, 483-493.	1.9	41
313	Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2021, 6, 918-932.	1.9	41
314	Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2022, 79, 2058-2068.	1.2	41
315	Comparison of Composite Measure Methodologies for Rewarding Quality of Care. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, 610-618.	0.9	40
316	Resting Ventricular Vascular Function and Exercise Capacity in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 580-589.	1.6	40
317	Comparison of Fatal or Irreversible Events With Extended Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	40
318	Weighing the Benefits and Risks of Proliferating Observational Treatment Assessments. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 625.	3.8	40
319	Variation in perioperative vasoactive therapy in cardiovascular surgical care: Data from the Society of Thoracic Surgeons. <i>American Heart Journal</i> , 2009, 158, 47-52.	1.2	39
320	Recent Nationwide Trends in Discharge Statin Treatment of Hospitalized Patients With Stroke. <i>Stroke</i> , 2010, 41, 1508-1513.	1.0	39
321	Associations between worsening renal function and 30-day outcomes among Medicare beneficiaries hospitalized with heart failure. <i>American Heart Journal</i> , 2010, 160, 132-138.e1.	1.2	39
322	Associations of Patient Demographic Characteristics and Regional Physician Density With Early Physician Follow-Up Among Medicare Beneficiaries Hospitalized With Heart Failure. <i>American Journal of Cardiology</i> , 2011, 108, 985-991.	0.7	39
323	Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2013, 15, 456-464.	2.9	39
324	Ten-Year Experience With Extended Criteria Cardiac Transplantation. <i>Circulation: Heart Failure</i> , 2013, 6, 1230-1238.	1.6	39

#	ARTICLE	IF	CITATIONS
325	Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee. <i>Journal of Cardiac Failure</i> , 2015, 21, 674-693.	0.7	39
326	Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 789-799.	1.9	39
327	Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , 2015, 170, 298-305.	1.2	38
328	Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	38
329	Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 348-356.	1.9	38
330	High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. <i>American Heart Journal</i> , 2018, 202, 97-103.	1.2	38
331	Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. <i>Diabetes Care</i> , 2020, 43, 643-652.	4.3	38
332	The Project Baseline Health Study: a step towards a broader mission to map human health. <i>Npj Digital Medicine</i> , 2020, 3, 84.	5.7	38
333	Impact of Left Ventricular Assist Device Bridging on Posttransplant Outcomes. <i>Annals of Thoracic Surgery</i> , 2009, 88, 1457-1461.	0.7	37
334	Are quality improvements associated with the Get With the Guidelines-Coronary Artery Disease (GTWG-CAD) program sustained over time?. <i>American Heart Journal</i> , 2010, 159, 207-214.	1.2	37
335	Representativeness of RELAX-AHF Clinical Trial Population in Acute Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 259-268.	0.9	37
336	Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-Hour Exclusions and Association With Outcome. <i>Stroke</i> , 2014, 45, 2745-2749.	1.0	37
337	Association of Hospital Performance Based on 30-Day Risk-Standardized Mortality Rate With Long-term Survival After Heart Failure Hospitalization. <i>JAMA Cardiology</i> , 2018, 3, 489.	3.0	37
338	Intravenous Tissue Plasminogen Activator in Stroke Mimics. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e005609.	0.9	37
339	High-Density Lipoprotein Particle Subfractions in Heart Failure With Preserved or Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2019, 73, 177-186.	1.2	37
340	Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations. <i>European Journal of Heart Failure</i> , 2021, 23, 1076-1084.	2.9	37
341	Comparative Effectiveness of β -Blockers in Elderly Patients With Heart Failure. <i>Archives of Internal Medicine</i> , 2008, 168, 2422.	4.3	36
342	Role of guanylate cyclase modulators in decompensated heart failure. <i>Heart Failure Reviews</i> , 2009, 14, 309-319.	1.7	36

#	ARTICLE	IF	CITATIONS
343	Standardizing care for acute decompensated heart failure in a large megatrial: The approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , 2009, 157, 219-228.	1.2	36
344	Postoperative Inotrope and Vasopressor Use Following CABG: Outcome Data from the CAPS-Care Study. <i>Journal of Cardiac Surgery</i> , 2011, 26, 572-578.	0.3	36
345	Patterns, Predictors, Variations, and Temporal Trends in Emergency Medical Service Hospital Prenotification for Acute Ischemic Stroke. <i>Journal of the American Heart Association</i> , 2012, 1, e002345.	1.6	36
346	Transient and persistent worsening renal function during hospitalization for acute heart failure. <i>American Heart Journal</i> , 2014, 168, 891-900.	1.2	36
347	Depressive Symptoms and Risk of Cardiovascular Events in Blacks. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 552-559.	0.9	36
348	The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2016, 18, 306-313.	2.9	36
349	Cardiac transplantation for older patients: Characteristics and outcomes in the septuagenarian population. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 362-369.	0.3	36
350	Leveraging electronic health records for clinical research. <i>American Heart Journal</i> , 2018, 202, 13-19.	1.2	36
351	Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. <i>Circulation: Heart Failure</i> , 2018, 11, e005400.	1.6	36
352	Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). <i>American Heart Journal</i> , 2011, 161, 418-424.e3.	1.2	35
353	Assessment of Dyspnea in Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1441-1448.	1.2	35
354	Association Between Prophylactic Implantable Cardioverter-Defibrillators and Survival in Patients With Left Ventricular Ejection Fraction Between 30% and 35%. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2209.	3.8	35
355	Racial/Ethnic Differences in Process of Care and Outcomes Among Patients Hospitalized With Intracerebral Hemorrhage. <i>Stroke</i> , 2014, 45, 3243-3250.	1.0	35
356	Chronic Kidney Disease and Bleeding Complications After Intravenous Thrombolytic Therapy for Acute Ischemic Stroke. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 929-935.	0.9	35
357	Comparative Assessment of Short-Term Adverse Events in Acute Heart Failure With Cystatin C and Other Estimates of Renal Function. <i>JACC: Heart Failure</i> , 2015, 3, 40-49.	1.9	35
358	Relation of Dyspnea Severity on Admission for Acute Heart Failure With Outcomes and Costs. <i>American Journal of Cardiology</i> , 2015, 115, 75-81.	0.7	35
359	Evidence from Pragmatic Trials during Routine Care – Slouching toward a Learning Health System. <i>New England Journal of Medicine</i> , 2020, 382, 1488-1491.	13.9	35
360	Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1300-1312.	2.9	35

#	ARTICLE	IF	CITATIONS
361	Improvement in use of anticoagulation therapy in patients with ischemic stroke: Results from Get With The Guidelinesâ€“Stroke. <i>American Heart Journal</i> , 2011, 162, 692-699.e2.	1.2	34
362	Use of Heart Failure Medical Therapies Among Patients With Left Ventricular Assist Devices: Insights From INTERMACS. <i>Journal of Cardiac Failure</i> , 2016, 22, 672-679.	0.7	34
363	Quality of Care and In-Hospital Outcomes in Patients With Coronary Heart Disease in Rural and Urban Hospitals (from Get With the Guidelinesâ€“Coronary Artery Disease Program). <i>American Journal of Cardiology</i> , 2010, 105, 139-143.	0.7	33
364	Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: An analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG). <i>American Heart Journal</i> , 2010, 160, 1130-1136.e3.	1.2	33
365	Use of Hydralazineâ€“Sorbitrate Combination in African American and Other Race/Ethnic Group Patients With Heart Failure and Reduced Left Ventricular Ejection Fraction. <i>Journal of the American Heart Association</i> , 2013, 2, e000214.	1.6	33
366	Hospital Variation in Home-Time After Acute Ischemic Stroke. <i>Stroke</i> , 2016, 47, 2627-2633.	1.0	33
367	Assessing Frailty in Patients Undergoing Destination Therapy Left Ventricular Assist Device: Observations from Interagency Registry for Mechanically Assisted Circulatory Support. <i>ASAIO Journal</i> , 2018, 64, 16-23.	0.9	33
368	Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. <i>Circulation</i> , 2019, 140, 1115-1124.	1.6	33
369	Rationale and Design of the VITALITY-HFpEF Trial. <i>Circulation: Heart Failure</i> , 2019, 12, e005998.	1.6	33
370	Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1390-1398.	2.9	33
371	2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, 162, e23-e106.	0.4	33
372	International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation. <i>American Heart Journal</i> , 2012, 163, 804-811.	1.2	32
373	Racial/Ethnic Differences in B-Type Natriuretic Peptide Levels and Their Association With Care and Outcomes Among Patients Hospitalized With Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 345-352.	1.9	32
374	Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	32
375	Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. <i>Journal of Cardiac Failure</i> , 2018, 24, 255-265.	0.7	32
376	Regional Differences in Quality of Care and Outcomes for the Treatment of Acute Coronary Syndromes. <i>Critical Pathways in Cardiology</i> , 2010, 9, 1-7.	0.2	31
377	Surgical Management of Bilateral Synchronous Kidney Tumors: Functional and Oncological Outcomes. <i>Journal of Urology</i> , 2010, 184, 865-872.	0.2	31
378	Trends in Clinical, Demographic, and Biochemical Characteristics of Patients With Acute Myocardial Infarction From 2003 to 2008: A Report From the American Heart Association Get With The Guidelines Coronary Artery Disease Program. <i>Journal of the American Heart Association</i> , 2012, 1, e001206.	1.6	31

#	ARTICLE	IF	CITATIONS
379	Patterns of Care Quality and Prognosis Among Hospitalized Ischemic Stroke Patients With Chronic Kidney Disease. <i>Journal of the American Heart Association</i> , 2014, 3, e000905.	1.6	31
380	Insurance Status and Outcome after Intracerebral Hemorrhage: Findings from Get With The Guidelines-Stroke. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2014, 23, 283-292.	0.7	31
381	Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction Trial. <i>Circulation: Heart Failure</i> , 2015, 8, 221-228.	1.6	31
382	Temporal Trends for Secondary Prevention Measures Among Patients Hospitalized with Coronary Artery Disease. <i>American Journal of Medicine</i> , 2015, 128, 426.e1-426.e9.	0.6	31
383	Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2017, 2, 896.	3.0	31
384	Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials. <i>Journal of Cardiac Failure</i> , 2018, 24, 428-438.	0.7	31
385	Association of the Affordable Care Act's Medicaid Expansion With Care Quality and Outcomes for Low-Income Patients Hospitalized With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004729.	0.9	31
386	Associations Between Use of the Hospitalist Model and Quality of Care and Outcomes of Older Patients Hospitalized for Heart Failure. <i>JACC: Heart Failure</i> , 2013, 1, 445-453.	1.9	30
387	Primary Prevention Implantable Cardioverter-Defibrillators and Survival in Older Women. <i>JACC: Heart Failure</i> , 2015, 3, 159-167.	1.9	30
388	Rationale and Design of the ATHENA-HF Trial. <i>JACC: Heart Failure</i> , 2016, 4, 726-735.	1.9	30
389	Association of Arterial Pulse Pressure With Long-Term Clinical Outcomes in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 42-49.	1.9	30
390	Vaccination Trends in Patients With Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 844-855.	1.9	30
391	Representativeness of a Heart Failure Trial by Race and Sex. <i>JACC: Heart Failure</i> , 2019, 7, 980-992.	1.9	30
392	Randomized Placebo-Controlled Trial of Ferric Carboxymaltose in Heart Failure With Iron Deficiency: Rationale and Design. <i>Circulation: Heart Failure</i> , 2021, 14, e008100.	1.6	30
393	Preoperative Evaluation for Major Noncardiac Surgery. <i>Archives of Internal Medicine</i> , 2004, 164, 1729.	4.3	29
394	The Importance of Consistent, High-Quality Acute Myocardial Infarction and Heart Failure Care. <i>Journal of the American College of Cardiology</i> , 2011, 58, 637-644.	1.2	29
395	Minding the Gap Between Efforts to Reduce Readmissions and Disparities. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 715.	3.8	29
396	Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. <i>Circulation: Heart Failure</i> , 2016, 9, e002444.	1.6	29

#	ARTICLE	IF	CITATIONS
397	Acute Heart Failure. JACC: Heart Failure, 2017, 5, 329-336.	1.9	29
398	Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes. American Heart Journal, 2017, 189, 48-58.	1.2	29
399	Association of Anemia with Venous Thromboembolism in Acutely Ill Hospitalized Patients: An APEX Trial Substudy. American Journal of Medicine, 2018, 131, 972.e1-972.e7.	0.6	29
400	Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. European Journal of Heart Failure, 2018, 20, 525-532.	2.9	29
401	International Comparison of Patient Characteristics and Quality of Care for Ischemic Stroke: Analysis of the China National Stroke Registry and the American Heart Association Get With The Guidelines-Stroke Program. Journal of the American Heart Association, 2018, 7, e010623.	1.6	29
402	The Burden of Congestion in Patients Hospitalized With Acute Decompensated Heart Failure. American Journal of Cardiology, 2019, 124, 545-553.	0.7	29
403	Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation. JAMA Cardiology, 2020, 5, 986.	3.0	29
404	Influence of stroke subtype on quality of care in the Get With The Guidelines-Stroke Program. Neurology, 2009, 73, 709-716.	1.5	28
405	Care and Outcomes of Asian-American Acute Myocardial Infarction Patients: Findings From the American Heart Association Get With The Guidelines-Coronary Artery Disease Program. Circulation: Cardiovascular Quality and Outcomes, 2012, 5, 126-133.	0.9	28
406	Reperfusion Strategies and Quality of Care in 5339 Patients Age 80 Years or Older Presenting With ST-Elevation Myocardial Infarction: Analysis from Get With The Guidelines-Coronary Artery Disease. Clinical Cardiology, 2012, 35, 632-640.	0.7	28
407	Guideline-Directed Low-Density Lipoprotein Management in High-Risk Patients With Ischemic Stroke. Stroke, 2014, 45, 3343-3351.	1.0	28
408	Hospital Variation in Intravenous Inotrope Use for Patients Hospitalized With Heart Failure. Circulation: Heart Failure, 2014, 7, 251-260.	1.6	28
409	Assessing the Quality and Comparative Effectiveness of Team-Based Care for Heart Failure. Heart Failure Clinics, 2015, 11, 499-506.	1.0	28
410	Smoking Paradox in Patients Hospitalized With Coronary Artery Disease or Acute Ischemic Stroke. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, S73-80.	0.9	28
411	Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. Circulation: Heart Failure, 2016, 9, e002630.	1.6	28
412	Discharge heart rate and β -blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry. American Heart Journal, 2016, 173, 172-178.	1.2	28
413	Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization. Circulation, 2017, 135, 2077-2080.	1.6	28
414	Machine learning to predict venous thrombosis in acutely ill medical patients. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 230-237.	1.0	28

#	ARTICLE	IF	CITATIONS
415	Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure. JACC: Heart Failure, 2021, 9, 293-300.	1.9	28
416	Association of Recent Use of Non-Vitamin K Antagonist Oral Anticoagulants With Intracranial Hemorrhage Among Patients With Acute Ischemic Stroke Treated With Alteplase. JAMA - Journal of the American Medical Association, 2022, 327, 760.	3.8	28
417	Acute Heart Failure. Circulation: Heart Failure, 2012, 5, 735-741.	1.6	27
418	Predicting Costs Among Medicare Beneficiaries With Heart Failure. American Journal of Cardiology, 2012, 109, 705-711.	0.7	27
419	Targeting the Kidney in Acute Heart Failure: Can Old Drugs Provide New Benefit?. Circulation: Heart Failure, 2013, 6, 1087-1094.	1.6	27
420	Comparative Effectiveness of Cardiac Resynchronization Therapy With an Implantable Cardioverter-Defibrillator Versus Defibrillator Therapy Alone. Annals of Internal Medicine, 2014, 160, 603.	2.0	27
421	Trends and outcomes of patients with adult congenital heart disease and pulmonary hypertension listed for orthotopic heart transplantation in the United States. Journal of Heart and Lung Transplantation, 2016, 35, 619-624.	0.3	27
422	Leveraging Behavioral Economics to Improve Heart Failure Care and Outcomes. Circulation, 2017, 136, 765-772.	1.6	27
423	Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients. Circulation, 2018, 137, 91-94.	1.6	27
424	Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. European Journal of Heart Failure, 2018, 20, 1601-1610.	2.9	27
425	Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double-blind, placebo-controlled trial. European Journal of Heart Failure, 2019, 21, 1426-1433.	2.9	27
426	The burden of non-cardiac comorbidities and association with clinical outcomes in an acute heart failure trial—insights from ASCEND-HF. European Journal of Heart Failure, 2020, 22, 1022-1031.	2.9	27
427	Pharmacotherapy in Medicare beneficiaries with atrial fibrillation. Heart Rhythm, 2012, 9, 1403-1408.	0.3	26
428	Predictors of Incident Heart Failure Hospitalizations Among Patients With Impaired Glucose Tolerance. Circulation: Heart Failure, 2013, 6, 203-210.	1.6	26
429	Hospitalized Hemorrhagic Stroke Patients with Renal Insufficiency: Clinical Characteristics, Care Patterns, and Outcomes. Journal of Stroke and Cerebrovascular Diseases, 2014, 23, 2265-2273.	0.7	26
430	Current quality of cardiovascular prevention for Million Hearts: An analysis of 147,038 outpatients from The Guideline Advantage. American Heart Journal, 2014, 168, 398-404.	1.2	26
431	Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease. Journal of the American College of Cardiology, 2015, 66, 2618-2629.	1.2	26
432	Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	26

#	ARTICLE	IF	CITATIONS
433	Characteristics and Treatments of Patients Enrolled in the CHAMPâ€HF Registry Compared With Patients Enrolled in the PARADIGMâ€HF Trial. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	26
434	Contemporary performance of surgical ventricular restoration procedures: Data from the Society of Thoracic Surgeons' National Cardiac Database. <i>American Heart Journal</i> , 2006, 152, 494-499.	1.2	25
435	Patient and hospital characteristics associated with traditional measures of inpatient quality of care for patients with heart failure. <i>American Heart Journal</i> , 2012, 163, 239-245.e3.	1.2	25
436	Global Variation in Quality of Care Among Patients Hospitalized With Acute Heart Failure in an International Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 534-542.	0.9	25
437	Achievement of Guideline-Concordant Care and In-Hospital Outcomes in Patients With Coronary Artery Disease in Teaching and Nonteaching Hospitals. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 58-65.	0.9	25
438	Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCENDâ€HF) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, e002092.	1.6	25
439	Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients With Acute Ischemic Stroke Taking Nonâ€Vitamin K Antagonist Oral Anticoagulants Preceding Stroke. <i>Stroke</i> , 2018, 49, 2237-2240.	1.0	25
440	Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the <sc>FIGHT</sc> trial. <i>ESC Heart Failure</i> , 2018, 5, 1035-1043.	1.4	25
441	Clinical Outcomes in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008018.	1.4	25
442	Diastolic Dysfunction in Patients With Human Immunodeficiency Virus Receiving Antiretroviral Therapy: Results From the CHART Study. <i>Journal of Cardiac Failure</i> , 2020, 26, 371-380.	0.7	25
443	Improvement in Left Ventricular Ejection Fraction in Outpatients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006833.	1.6	25
444	Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. <i>American Journal of Cardiology</i> , 2020, 126, 94-102.	0.7	25
445	Sex Differences in the Management and Outcomes of Heart Failure With Preserved Ejection Fraction in Patients Presenting to the Emergency Department With Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, 781-788.	0.7	24
446	Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	24
447	Improving Care for Patients after Hospitalization with AKI. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2237-2241.	3.0	24
448	Prognostic Role of Prior Heart Failure Hospitalization Among Patients Hospitalized for Worsening Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2021, 14, e007871.	1.6	24
449	Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: Results from the PProject of Ex-vivo Vein graft ENgineering via Transfection IV Trial. <i>American Heart Journal</i> , 2015, 169, 175-184.	1.2	23
450	Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs. <i>American Journal of Cardiology</i> , 2016, 117, 946-951.	0.7	23

#	ARTICLE	IF	CITATIONS
451	Serum Bicarbonate in Acute Heart Failure: Relationship to Treatment Strategies and Clinical Outcomes. <i>Journal of Cardiac Failure</i> , 2016, 22, 738-742.	0.7	23
452	Resting Heart Rate and Long-term Outcomes Among the African American Population. <i>JAMA Cardiology</i> , 2017, 2, 172.	3.0	23
453	Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. <i>Diabetes Care</i> , 2019, 42, 318-326.	4.3	23
454	Sex Differences in Clinical Course and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 336-345.	1.9	23
455	Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e021094.	1.6	23
456	Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry. <i>Journal of Cardiac Failure</i> , 2022, 28, 1063-1077.	0.7	23
457	Use of Guideline-Recommended Therapies for Heart Failure in the Medicare Population. <i>Clinical Cardiology</i> , 2010, 33, 400-405.	0.7	22
458	Differences in Treatment, Outcomes, and Quality of Life Among Patients With Heart Failure in Canada and the United States. <i>JACC: Heart Failure</i> , 2013, 1, 523-530.	1.9	22
459	Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2015, 17, 340-346.	2.9	22
460	Cluster-Randomized Trial of Personalized Site Performance Feedback in Get With The Guidelines-Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 421-427.	0.9	22
461	Guideline-Appropriate Care and In-Hospital Outcomes in Patients With Heart Failure in Teaching and Nonteaching Hospitals. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 757-766.	0.9	22
462	Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 241-249.	2.9	22
463	Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2389-2395.	1.8	22
464	High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. <i>Journal of the American Heart Association</i> , 2018, 7, e010364.	1.6	22
465	Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. <i>Clinical Cardiology</i> , 2018, 41, 945-952.	0.7	22
466	Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019, 140, 2108-2118.	1.6	22
467	Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF. <i>American Heart Journal</i> , 2020, 220, 41-50.	1.2	22
468	Multiple cardiac sensors for management of heart failure (MANAGE-HF) - Phase I Evaluation of the Integration and Safety of the HeartLogic Multisensor Algorithm in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 1245-1254.	0.7	22

#	ARTICLE	IF	CITATIONS
469	Addressing disparities in sudden cardiac arrest care and the underutilization of effective therapies. <i>American Heart Journal</i> , 2010, 160, 605-618.e1.	1.2	21
470	Diabetes, quality of care, and in-hospital outcomes in patients hospitalized with heart failure. <i>American Heart Journal</i> , 2011, 162, 480-486.e3.	1.2	21
471	Utilization of Hospice and Predicted Mortality Risk Among Older Patients Hospitalized With Heart Failure: Findings From GWTC-HF. <i>Journal of Cardiac Failure</i> , 2012, 18, 471-477.	0.7	21
472	Are Racial/Ethnic Gaps in the Use of Cardiac Resynchronization Therapy Narrowing?. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1577-1578.	1.2	21
473	Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients. <i>Circulation: Heart Failure</i> , 2013, 6, 862-868.	1.6	21
474	Medicare Expenditures by Race/Ethnicity After Hospitalization for Heart Failure With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2018, 6, 388-397.	1.9	21
475	Circulating Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2020, 8, 70-80.	1.9	21
476	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). <i>Circulation</i> , 2021, 144, 1489-1499.	1.6	21
477	Influence of Hospital Length of Stay for Heart Failure on Quality of Care. <i>American Journal of Cardiology</i> , 2008, 102, 1693-1697.	0.7	20
478	Infectious Complications in Extended Criteria Heart Transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2008, 27, 1217-1221.	0.3	20
479	Clinical Effectiveness of Cardiac Resynchronization Therapy Versus Medical Therapy Alone Among Patients With Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 926-934.	1.6	20
480	Adherence and Persistence in the Use of Warfarin After Hospital Discharge Among Patients With Heart Failure and Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , 2014, 20, 23-30.	0.7	20
481	Ventricular Conduction and Long-Term Heart Failure Outcomes and Mortality in African Americans. <i>Circulation: Heart Failure</i> , 2015, 8, 243-251.	1.6	20
482	Effect of extended duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1913-1922.	1.9	20
483	Early Ambulation Among Hospitalized Heart Failure Patients Is Associated With Reduced Length of Stay and 30-Day Readmissions. <i>Circulation: Heart Failure</i> , 2018, 11, e004634.	1.6	20
484	Association of Changes in Heart Failure Treatment With Patients' Health Status. <i>JACC: Heart Failure</i> , 2019, 7, 615-625.	1.9	20
485	Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 777-785.	1.9	19
486	Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	19

#	ARTICLE	IF	CITATIONS
487	The Obesity and Heart Failure Epidemics Among African Americans: Insights From the Jackson Heart Study. <i>Journal of Cardiac Failure</i> , 2016, 22, 589-597.	0.7	19
488	Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. <i>American Heart Journal</i> , 2018, 198, 84-90.	1.2	19
489	Effect of Once-Weekly Exenatide on Clinical Outcomes According to Baseline Risk in Patients With Type 2 Diabetes Mellitus: Insights From the EXSCLE Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e009304.	1.6	19
490	Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF). <i>American Journal of Cardiology</i> , 2019, 124, 1900-1906.	0.7	19
491	Spirolactone in Acute Heart Failure Patients With Renal Dysfunction and Risk Factors for Diuretic Resistance: From the ATHENA-HF Trial. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1097-1105.	0.8	19
492	Left Ventricular Assessment in Myocardial Infarction. <i>Archives of Internal Medicine</i> , 2005, 165, 2162.	4.3	18
493	Quality of Care and Outcomes Among Patients With Acute Myocardial Infarction by Level of Kidney Function at Admission: Report From the Get With The Guidelines Coronary Artery Disease Program. <i>Clinical Cardiology</i> , 2012, 35, 541-547.	0.7	18
494	Comparison of Performance Achievement Award Recognition With Primary Stroke Center Certification for Acute Ischemic Stroke Care. <i>Journal of the American Heart Association</i> , 2013, 2, e000451.	1.6	18
495	Temporal trends in clinical characteristics of patients without known cardiovascular disease with a first episode of myocardial infarction. <i>American Heart Journal</i> , 2014, 167, 480-488.e1.	1.2	18
496	Lack of Impact of Electronic Health Records on Quality of Care and Outcomes for Ischemic Stroke. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1964-1972.	1.2	18
497	Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2017, 10, .	0.9	18
498	Data Sharing and Embedded Research. <i>Annals of Internal Medicine</i> , 2017, 167, 668.	2.0	18
499	Association of Kidney Function With 30-Day and 1-Year Poststroke Mortality and Hospital Readmission. <i>Stroke</i> , 2018, 49, 2896-2903.	1.0	18
500	Association of post-discharge specialty outpatient visits with readmissions and mortality in high-risk heart failure patients. <i>American Heart Journal</i> , 2019, 212, 101-112.	1.2	18
501	Hospital Factors Associated With Interhospital Transfer Destination for Stroke in the Northeast United States. <i>Journal of the American Heart Association</i> , 2020, 9, e011575.	1.6	18
502	Sample size requirements for detecting treatment effect heterogeneity in cluster randomized trials. <i>Statistics in Medicine</i> , 2020, 39, 4218-4237.	0.8	18
503	Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006645.	1.6	18
504	Weekend/Holiday Versus Weekday Hospital Discharge and Guideline Adherence (from the American) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf Cardiology</i> , 2008, 102, 663-667.	0.7	17

#	ARTICLE	IF	CITATIONS
505	Do heart failure disease management programs make financial sense under a bundled payment system?. American Heart Journal, 2011, 161, 916-922.	1.2	17
506	Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: Findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD). American Heart Journal, 2011, 162, 283-290.e2.	1.2	17
507	Use and Predictors of Heart Failure Disease Management Referral in Patients Hospitalized With Heart Failure: Insights From the Get With the Guidelines Program. Journal of Cardiac Failure, 2011, 17, 431-439.	0.7	17
508	Comparative Effectiveness of Pharmacotherapies for Prevention of Atrial Fibrillation Following Coronary Artery Bypass Surgery. American Journal of Cardiology, 2013, 112, 954-960.	0.7	17
509	A Crisis of the Heart. ASAIO Journal, 2013, 59, 668-670.	0.9	17
510	Characteristics and Outcomes of Patients With Heart Failure and Discordant Findings by Right-Sided Heart Catheterization and Cardiopulmonary Exercise Testing. American Journal of Cardiology, 2014, 114, 1059-1064.	0.7	17
511	Does Age Influence Cardiac Resynchronization Therapy Use and Outcome?. JACC: Heart Failure, 2015, 3, 497-504.	1.9	17
512	Comparison of 2-Year Outcomes of Extended Criteria Cardiac Transplantation Versus Destination Left Ventricular Assist Device Therapy Using Continuous Flow. American Journal of Cardiology, 2015, 116, 573-579.	0.7	17
513	Pulmonary Hypertension in the Era of Mechanical Circulatory Support. ASAIO Journal, 2016, 62, 505-512.	0.9	17
514	Statin use, intensity, and 3-year clinical outcomes among older patients with coronary artery disease. American Heart Journal, 2016, 173, 27-34.	1.2	17
515	Healthcare Resource Availability, Quality of Care, and Acute Ischemic Stroke Outcomes. Journal of the American Heart Association, 2017, 6, .	1.6	17
516	Sex and Age Interactions and Differences in Outcomes After Intracerebral Hemorrhage. Journal of Women's Health, 2017, 26, 380-388.	1.5	17
517	Long-term outcomes for heart failure patients with and without diabetes: From the Get With The Guidelinesâ€œHeart Failure Registry. American Heart Journal, 2019, 211, 1-10.	1.2	17
518	Extended-duration betrixaban versus shorter-duration enoxaparin for venous thromboembolism prophylaxis in critically ill medical patients: an APEX trial substudy. Intensive Care Medicine, 2019, 45, 477-487.	3.9	17
519	Association of Early Multiple Organ Dysfunction With Clinical and Functional Outcomes Over the Year Following Traumatic Brain Injury: A Transforming Research and Clinical Knowledge in Traumatic Brain Injury Study. Critical Care Medicine, 2021, 49, 1769-1778.	0.4	17
520	Impact of Percutaneous Coronary Intervention on Outcomes in Patients With Heart Failure. Journal of the American College of Cardiology, 2021, 77, 2432-2447.	1.2	17
521	Association of insurance status with inpatient treatment for coronary artery disease: Findings from the Get With the Guidelines program. American Heart Journal, 2010, 159, 1026-1036.	1.2	16
522	Quality of Care for Patients With Acute Coronary Syndromes as a Function of Hospital Revascularization Capability: Insights From Get With The Guidelinesâ€œCAD</sc>. Clinical Cardiology, 2014, 37, 285-292.	0.7	16

#	ARTICLE	IF	CITATIONS
523	Temporal Trends in Care and Outcomes of Patients Receiving Fibrinolytic Therapy Compared to Primary Percutaneous Coronary Intervention: Insights From the Get With The Guidelines Coronary Artery Disease (GWTG-CAD) Registry. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	16
524	Trends in the Use of Guideline-Directed Therapies Among Dialysis Patients Hospitalized With Systolic Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 649-661.	1.9	16
525	Association of Electronic Health Record Use With Quality of Care and Outcomes in Heart Failure: An Analysis of Get With The Guidelines Heart Failure. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	16
526	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). <i>American Journal of Cardiology</i> , 2018, 122, 1506-1512.	0.7	16
527	Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy. <i>Journal of Cardiac Failure</i> , 2021, 27, 670-676.	0.7	16
528	Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. <i>Journal of Cardiac Failure</i> , 2022, 28, 370-384.	0.7	16
529	Achieving More Rapid Door-to-Needle Times and Improved Outcomes in Acute Ischemic Stroke in a Nationwide Quality Improvement Intervention. <i>Stroke</i> , 2022, 53, 1328-1338.	1.0	16
530	Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 782-790.	2.9	16
531	Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. <i>JACC: Heart Failure</i> , 2022, 10, 198-210.	1.9	16
532	The future of cardiovascular clinical research in North America and beyond—addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. <i>American Heart Journal</i> , 2015, 169, 743-750.	1.2	15
533	Quality of Care and Ischemic Stroke Risk After Hospitalization for Transient Ischemic Attack. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, S117-S124.	0.9	15
534	Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	15
535	Cardiovascular events and hospital resource utilization pre- and post-transcatheter mitral valve repair in high-surgical risk patients. <i>American Heart Journal</i> , 2017, 189, 146-157.	1.2	15
536	Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.7	15
537	Health Status Variation Across Practices in Outpatients With Heart Failure. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004668.	0.9	15
538	Characteristics of Acute Heart Failure Hospitalizations Based on Presenting Severity. <i>Circulation: Heart Failure</i> , 2019, 12, e005171.	1.6	15
539	Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes Care</i> , 2019, 42, 1075-1080.	4.3	15
540	Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 223-225.	0.6	15

#	ARTICLE	IF	CITATIONS
541	Strict Versus Lenient Versus Poor Rate Control Among Patients With Atrial Fibrillation and Heart Failure (from the Get With The Guidelines “Heart Failure Program). American Journal of Cardiology, 2020, 125, 894-900.	0.7	15
542	Association Between Switching to a High-Deductible Health Plan and Major Cardiovascular Outcomes. JAMA Network Open, 2020, 3, e208939.	2.8	15
543	Association of Implantable Device Measured Physical Activity With Hospitalization for Heart Failure. JACC: Heart Failure, 2020, 8, 280-288.	1.9	15
544	Is Learning Worth the Trouble? “Improving Health Care System Participation in Embedded Research. New England Journal of Medicine, 2021, 385, 5-7.	13.9	15
545	Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. European Journal of Heart Failure, 2022, 24, 1614-1622.	2.9	15
546	Fast Partial-Differential Synthesis of the Matching Polynomial of C72-100. Journal of Chemical Information and Computer Sciences, 1998, 38, 1105-1110.	2.8	14
547	Clinical Commentary on “Certain Uncertainty: Life After Stroke From the Patient’s Perspective”, Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 970-970.	0.9	14
548	Acute decompensated heart failure patients admitted to critical care units: Insights from ASCEND-HF. International Journal of Cardiology, 2014, 177, 840-846.	0.8	14
549	Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. Journal of the American Heart Association, 2015, 4, e002061.	1.6	14
550	Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. European Journal of Heart Failure, 2016, 18, 684-692.	2.9	14
551	Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE). American Heart Journal, 2016, 178, 198-205.	1.2	14
552	When academic research organizations and clinical research organizations disagree: Processes to minimize discrepancies prior to unblinding of randomized trials. American Heart Journal, 2017, 189, 1-8.	1.2	14
553	Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. Journal of Thrombosis and Thrombolysis, 2018, 45, 1-8.	1.0	14
554	National Hospital Quality Rankings. JAMA - Journal of the American Medical Association, 2020, 324, 839.	3.8	14
555	When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?. Clinical Pharmacology and Therapeutics, 2022, 111, 108-115.	2.3	14
556	Epinephrine Activation of the β_2 -Adrenoceptor Is Required for IL-13-Induced Mucin Production in Human Bronchial Epithelial Cells. PLoS ONE, 2015, 10, e0132559.	1.1	14
557	Heart Failure With Preserved Left Ventricular Systolic Function Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes. American Journal of Cardiology, 2007, 99, 1351-1356.	0.7	13
558	Comparative effectiveness of angiotensin-converting-enzyme inhibitors: Is an ACE always an ace?. Cmaj, 2008, 178, 1316-1319.	0.9	13

#	ARTICLE	IF	CITATIONS
559	Regional differences in clinical profile, quality of care, and outcomes among Hispanic patients hospitalized with acute myocardial infarction in the Get with Guidelines® Coronary Artery Disease (GWTG-CAD) Registry. <i>American Heart Journal</i> , 2011, 162, 988-995.e4.	1.2	13
560	Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	13
561	Management of newly treated diabetes in Medicare beneficiaries with and without heart failure. <i>Clinical Cardiology</i> , 2017, 40, 38-45.	0.7	13
562	Intra-Aortic Balloon Pump Use Before Left Ventricular Assist Device Implantation: Insights From the INTERMACS Registry. <i>ASAIO Journal</i> , 2018, 64, 218-224.	0.9	13
563	Timing of Postdischarge Follow-up and Medication Adherence Among Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	13
564	A Hospital Level Analysis of 30-Day Readmission Performance for Heart Failure Patients and Long-Term Survival: Findings from Get With The Guidelines-Heart Failure. <i>American Heart Journal</i> , 2018, 200, 127-133.	1.2	13
565	Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease. <i>Circulation</i> , 2018, 138, 2576-2578.	1.6	13
566	Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004783.	0.9	13
567	Relationship Between Hospital Characteristics and Early Adoption of Angiotensin Receptor/Neprilysin Inhibitor Among Eligible Patients Hospitalized for Heart Failure. <i>Journal of the American Heart Association</i> , 2019, 8, e010484.	1.6	13
568	Testing for Coronary Artery Disease in Older Patients With New-Onset Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006963.	1.6	13
569	2020 American Heart Association and American College of Cardiology Consensus Conference on Professionalism and Ethics: A Consensus Conference Report. <i>Circulation</i> , 2021, 143, e1035-e1087.	1.6	13
570	Drug Repurposing for Glioblastoma and Current Advances in Drug Delivery—A Comprehensive Review of the Literature. <i>Biomolecules</i> , 2021, 11, 1870.	1.8	13
571	Rapid Change in Prescribing Behavior in Hospitals Participating in Get With The Guidelines® Stroke After Release of the Management of Atherothrombosis With Clopidogrel in High-Risk Patients (MATCH) Clinical Trial Results. <i>Stroke</i> , 2010, 41, 2094-2097.	1.0	12
572	Pharmacologic Prophylaxis for Venous Thromboembolism and 30-Day Outcomes Among Older Patients Hospitalized With Heart Failure: An Analysis From the ADHERE National Registry Linked to Medicare Claims. <i>Clinical Cardiology</i> , 2011, 34, 682-688.	0.7	12
573	B-type natriuretic peptide level and postdischarge thrombotic events in older patients hospitalized with heart failure: Insights from the Acute Decompensated Heart Failure National Registry. <i>American Heart Journal</i> , 2012, 163, 994-1001.	1.2	12
574	Medical Resource Use, Costs, and Quality of Life in Patients With Acute Decompensated Heart Failure: Findings From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2013, 19, 611-620.	0.7	12
575	The meanings associated with medicines in heart failure patients. <i>European Journal of Cardiovascular Nursing</i> , 2013, 12, 276-283.	0.4	12
576	Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. <i>American Heart Journal</i> , 2016, 182, 28-35.	1.2	12

#	ARTICLE	IF	CITATIONS
595	N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 457-465.	1.0	11
596	Recent Myocardial Infarction is Associated With Increased Risk in Older Adults With Acute Ischemic Stroke Receiving Thrombolytic Therapy. <i>Journal of the American Heart Association</i> , 2019, 8, e012450.	1.6	11
597	Hospital-based quality improvement interventions for patients with heart failure: a systematic review. <i>Heart</i> , 2019, 105, 431-438.	1.2	11
598	Prognostic Implications of Changes in Amino-Terminal Pro-B-Type Natriuretic Peptide in Acute Decompensated Heart Failure: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2019, 25, 703-711.	0.7	11
599	Thrombolytic therapy in older acute ischemic stroke patients with gastrointestinal malignancy or recent bleeding. <i>European Stroke Journal</i> , 2020, 5, 47-55.	2.7	11
600	Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 798-806.	2.2	11
601	Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting. <i>Therapeutic Innovation and Regulatory Science</i> , 2020, 54, 1477-1488.	0.8	11
602	Ultrafiltration in Acute Heart Failure: Implications of Ejection Fraction and Early Response to Treatment From CARRESS-HF. <i>Journal of the American Heart Association</i> , 2020, 9, e015752.	1.6	11
603	Impact of the COVID-19 Pandemic on Cardiovascular Science: Anticipating Problems and Potential Solutions: A Presidential Advisory From the American Heart Association. <i>Circulation</i> , 2021, 144, e461-e471.	1.6	11
604	Use of Renin-Angiotensin System Blockers in Acute Coronary Syndromes. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 227-235.	0.9	10
605	Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2017, 377, 2502-2502.	13.9	10
606	Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry. <i>American Heart Journal</i> , 2018, 198, 123-128.	1.2	10
607	Trends and outcomes of cardiac transplantation from donors dying of drug intoxication. <i>American Heart Journal</i> , 2018, 199, 92-96.	1.2	10
608	The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes. <i>Clinical Cardiology</i> , 2018, 41, 1259-1267.	0.7	10
609	Assessing heterogeneity of treatment effect analyses in health-related cluster randomized trials: A systematic review. <i>PLoS ONE</i> , 2019, 14, e0219894.	1.1	10
610	Intravenous Tissue-Type Plasminogen Activator in Acute Ischemic Stroke Patients With History of Stroke Plus Diabetes Mellitus. <i>Stroke</i> , 2019, 50, 1497-1503.	1.0	10
611	Ischemic Stroke Transfer Patterns in the Northeast United States. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 295-304.	0.7	10
612	History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 47-55.	1.9	10

#	ARTICLE	IF	CITATIONS
613	Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. <i>Journal of Cardiac Failure</i> , 2020, 26, 270-275.	0.7	10
614	Racial and Ethnic Differences in Health Care Utilization Following Severe Acute Brain Injury in the United States. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 1258-1263.	1.3	10
615	The Status of Specialized Ambulatory Heart Failure Care in Canada: A Joint Canadian Heart Failure Society and Canadian Cardiovascular Society Heart Failure Guidelines Survey. <i>CJC Open</i> , 2020, 2, 151-160.	0.7	10
616	Association of Severe Acute Kidney Injury with Mortality and Healthcare Utilization Following Isolated Traumatic Brain Injury. <i>Neurocritical Care</i> , 2021, 35, 434-440.	1.2	10
617	Return of individual research results: What do participants prefer and expect?. <i>PLoS ONE</i> , 2021, 16, e0254153.	1.1	10
618	The use of electronic health records for recruitment in clinical trials: a mixed methods analysis of the Harmony Outcomes Electronic Health Record Ancillary Study. <i>Trials</i> , 2021, 22, 465.	0.7	10
619	Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Journal of the American Heart Association</i> , 2021, 10, e021459.	1.6	10
620	Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry. <i>Circulation: Heart Failure</i> , 2021, 14, e008351.	1.6	10
621	Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	1.6	10
622	Quality of care for sudden cardiac arrest: Proposed steps to improve the translation of evidence into practice. <i>American Heart Journal</i> , 2011, 162, 222-231.	1.2	9
623	The association between meteorological events and acute heart failure: New insights from ASCEND-HF. <i>International Journal of Cardiology</i> , 2014, 177, 819-824.	0.8	9
624	Recognition of biomarker identified high-risk patients in the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban study resulting in a protocol amendment. <i>American Heart Journal</i> , 2015, 169, 186-187.	1.2	9
625	Trends in the Care and Outcomes of Medicare Beneficiaries with Type 2 Diabetes, 2002â€“2011. <i>Endocrine Practice</i> , 2016, 22, 920-934.	1.1	9
626	Finerenone in heart failure: walking a fine line. <i>European Heart Journal</i> , 2016, 37, 2115-2117.	1.0	9
627	Evaluation of a provocative dyspnea severity score in acute heart failure. <i>American Heart Journal</i> , 2016, 172, 34-41.	1.2	9
628	Dichotomous Relationship Between Age and 30-Day Death or Rehospitalization in Heart Failure Patients Admitted With Acute Decompensated Heart Failure: Results From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2016, 22, 409-416.	0.7	9
629	Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016, 21, 227-232.	1.0	9
630	Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function. <i>American Journal of Cardiology</i> , 2017, 119, 886-892.	0.7	9

#	ARTICLE	IF	CITATIONS
631	Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes. <i>Clinical Cardiology</i> , 2019, 42, 256-263.	0.7	9
632	Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 512-519.	0.7	9
633	Exploring the Possible Impact of Unbalanced Open-Label Drop-In of Glucose-Lowering Medications on EXSCEL Outcomes. <i>Circulation</i> , 2020, 141, 1360-1370.	1.6	9
634	Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial. <i>Journal of Cardiac Failure</i> , 2020, 26, 233-242.	0.7	9
635	Streamlining the institutional review board process in pragmatic randomized clinical trials: challenges and lessons learned from the Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) trial. <i>Trials</i> , 2021, 22, 90.	0.7	9
636	Enabling patient-reported outcome measures in clinical trials, exemplified by cardiovascular trials. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 164.	1.0	9
637	Validation of Cardiovascular End Points Ascertainment Leveraging Multisource Electronic Health Records Harmonized Into a Common Data Model in the ADAPTABLE Randomized Clinical Trial. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, CIRCOUTCOMES121008190.	0.9	9
638	Who Enrolls in the Medicare Part D Prescription Drug Benefit Program? Medication Use Among Patients With Heart Failure. <i>Journal of the American Heart Association</i> , 2013, 2, e000242.	1.6	8
639	Differences in health care use and outcomes by the timing of in-hospital worsening heart failure. <i>American Heart Journal</i> , 2015, 170, 1124-1132.	1.2	8
640	Heart failure medications prescribed at discharge for patients with left ventricular assist devices. <i>American Heart Journal</i> , 2016, 179, 99-106.	1.2	8
641	Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy. <i>Pharmaceutical Statistics</i> , 2017, 16, 445-450.	0.7	8
642	Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure. <i>American Heart Journal</i> , 2018, 200, 134-140.	1.2	8
643	Association of D-dimer Levels with Clinical Event Rates and the Efficacy of Betrixaban versus Enoxaparin in the APEX Trial. <i>TH Open</i> , 2018, 02, e16-e24.	0.7	8
644	Speckle Tracking Analysis of Left Ventricular Systolic Function Following Traumatic Brain Injury: A Pilot Prospective Observational Cohort Study. <i>Journal of Neurosurgical Anesthesiology</i> , 2020, 32, 156-161.	0.6	8
645	PROVIDE-HF primary results: Patient-Reported Outcomes in Investigation following Initiation of Drug therapy with Entresto (sacubitril/valsartan) in heart failure. <i>American Heart Journal</i> , 2020, 230, 35-43.	1.2	8
646	Effects of Liraglutide on Worsening Renal Function Among Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2020, 13, e006758.	1.6	8
647	Growth differentiation factor-15, treatment with liraglutide, and clinical outcomes among patients with heart failure. <i>ESC Heart Failure</i> , 2021, 8, 2608-2616.	1.4	8
648	Clinical Outcome Predictions for the Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 949-956.	0.7	8

#	ARTICLE	IF	CITATIONS
649	Implantable left ventricular assist devices: new hope for patients with end-stage heart failure. North Carolina Medical Journal, 2006, 67, 110-5.	0.1	8
650	The association of improvement in left ventricular ejection fraction with outcomes in patients with heart failure with reduced ejection fraction: data from <sc>CHAMP&HF</sc>. European Journal of Heart Failure, 2022, 24, 762-770.	2.9	8
651	Association Between Mortality and Persistent Use of Beta Blockers and Angiotensin-Converting Enzyme Inhibitors in Patients With Left Ventricular Systolic Dysfunction and Coronary Artery Disease. American Journal of Cardiology, 2009, 103, 1518-1524.	0.7	7
652	Clinical Outcomes at 180 days in the ASCEND-HF Trial: Double-Blind, Placebo-Controlled, Multicenter Acute Study of Clinical Effectiveness of Nesiritide in Subjects With Decompensated Heart Failure. Journal of Cardiac Failure, 2011, 17, 971.	0.7	7
653	Prediction Is Very Hard, Especially About the Future. Archives of Internal Medicine, 2012, 172, 117.	4.3	7
654	Completion of Guideline&Recommended Initial Evaluation of Atrial Fibrillation. Clinical Cardiology, 2012, 35, 585-593.	0.7	7
655	Trends in Smoking Cessation Counseling: Experience From American Heart Association&Get With The Guidelines. Clinical Cardiology, 2012, 35, 396-403.	0.7	7
656	Clinical Effectiveness of Anticoagulation Therapy Among Older Patients With Heart Failure and Without Atrial Fibrillation: Findings From the ADHERE Registry Linked to Medicare Claims. Journal of Cardiac Failure, 2013, 19, 401-407.	0.7	7
657	Priorities for Comparative Effectiveness Reviews in Cardiovascular Disease. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 139-147.	0.9	7
658	Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score. Journal of Cardiac Failure, 2016, 22, 853-858.	0.7	7
659	Impact of an Expanded Hospital Recognition Program for Stroke Quality of Care. Journal of the American Heart Association, 2017, 6, .	1.6	7
660	Engaging patients throughout the health system: A landscape analysis of cold-call policies and recommendations for future policy change. Journal of Clinical and Translational Science, 2018, 2, 384-392.	0.3	7
661	2018 ACC/HRS/NASCI/SCAI/SCCT Expert Consensus Document on Optimal Use of Ionizing Radiation in Cardiovascular Imaging&Best Practices for Safety and Effectiveness, Part 1: Radiation Physics and Radiation Biology. Catheterization and Cardiovascular Interventions, 2018, 92, 203-221.	0.7	7
662	Estimation of Acutely Ill Medical Patients at Venous Thromboembolism Risk Eligible for Extended Thromboprophylaxis Using APEX Criteria in US Hospitals. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961988000.	0.7	7
663	Addressing guideline and policy changes during pragmatic clinical trials. Clinical Trials, 2019, 16, 431-437.	0.7	7
664	Transitioning to the National Institutes of Health single institutional review board model: Piloting the use of the Streamlined, Multi-site, Accelerated Resources for Trials IRB Reliance. Clinical Trials, 2019, 16, 290-296.	0.7	7
665	Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. Circulation, 2019, 139, 1234-1236.	1.6	7
666	Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations. American Heart Journal, 2020, 226, 13-23.	1.2	7

#	ARTICLE	IF	CITATIONS
667	Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 643-651.	3.0	7
668	Trends in Treatment for Patients Hospitalized with Heart Failure with Preserved Ejection Fraction Before and After Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT). <i>American Journal of Cardiology</i> , 2020, 125, 1655-1660.	0.7	7
669	Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities. <i>American Heart Journal</i> , 2021, 235, 82-96.	1.2	7
670	Association between sacubitril/valsartan initiation and real-world health status trajectories over 18 months in heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 2670-2678.	1.4	7
671	Transmethylamine Oxide Is Associated With Diffuse Cardiac Fibrosis in People Living With HIV. <i>Journal of the American Heart Association</i> , 2021, 10, e020499.	1.6	7
672	Racial/Ethnic Disparities in Healthcare Worker Experiences During the COVID-19 Pandemic: An Analysis of the HERO Registry. <i>EClinicalMedicine</i> , 2022, 45, 101314.	3.2	7
673	Health System Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients with HFrEF: Results from the CONNECT-HF Trial. <i>Journal of Cardiac Failure</i> , 2022, , .	0.7	7
674	The Potential Impact of Expanding Cardiac Rehabilitation in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 68, 977-978.	1.2	6
675	2018 ACC/HRS/NASCI/SCAI/SCCT Expert Consensus Document on Optimal Use of Ionizing Radiation in Cardiovascular Imaging Best Practices for Safety and Effectiveness, Part 2: Radiological Equipment Operation, Dose-Sparing Methodologies, Patient and Medical Personnel Protection. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 222-246.	0.7	6
676	The Association of Black Cardiologists (ABC) Cardiovascular Implementation Study (CVIS): A Research Registry Integrating Social Determinants to Support Care for Underserved Patients. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 1631.	1.2	6
677	Incidence of statin use in older adults with and without cardiovascular disease and diabetes mellitus, January 2008- March 2018. <i>PLoS ONE</i> , 2019, 14, e0223515.	1.1	6
678	Extended prophylaxis of venous thromboembolism with betrixaban in acutely ill medical patients with and without cancer: insights from the APEX trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 214-219.	1.0	6
679	Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?. <i>American Heart Journal</i> , 2020, 220, 97-107.	1.2	6
680	Eligibility of sodium-glucose cotransporter 2 inhibitors among patients with diabetes mellitus admitted for heart failure. <i>ESC Heart Failure</i> , 2020, 7, 275-279.	1.4	6
681	Heart Failure Clinical Trial Operations During the COVID-19 Pandemic. <i>Circulation: Heart Failure</i> , 2020, 13, e007456.	1.6	6
682	Generating evidence for therapeutic effects: the need for well-conducted randomized trials. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	6
683	Treatment Persistence of Renin-Angiotensin-Aldosterone-System Inhibitors Over Time in Heart Failure with Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2022, 28, 191-201.	0.7	6
684	Polyvascular disease and increased risk of cardiovascular events in patients with type 2 diabetes: Insights from the EXSCCEL trial. <i>Atherosclerosis</i> , 2021, 338, 1-6.	0.4	6

#	ARTICLE	IF	CITATIONS
685	Research Goes Red: Early Experience With a Participant-Centric Registry. <i>Circulation Research</i> , 2022, 130, 343-351.	2.0	6
686	The impact of COVID-19 on pragmatic clinical trials: lessons learned from the NIH Health Care Systems Research Collaboratory. <i>Trials</i> , 2022, 23, .	0.7	6
687	Patterns and Implications of B-type Natriuretic Peptide Measurement in Patients With Nonâ€œST-Segment Elevation Acute Coronary Syndromesâ€œConflicts of interest: L. Kristin Newby receives research grants from Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, the Schering Plough Research Institute, and BMS/Sanofi and is a member of the speakers bureau and receives honoraria from BMS/Sanofi/Aventis. W. Frank Peacock receives research grants from and is a member of the speakers bureau and the consultant. <i>American Journal of Cardiology</i> , 2007, 100, 1727-1733.	0.7	5
688	Dysphagia in the Setting of Left Ventricular Assist Device Hemolysis. <i>ASAIO Journal</i> , 2013, 59, 322-323.	0.9	5
689	Associations Between Anticoagulation Therapy and Risks of Mortality and Readmission Among Patients With Heart Failure and Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 670-679.	0.9	5
690	Associations Between Blood Pressure and Outcomes Among Blacks in the Jackson Heart Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	5
691	Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score. <i>American Heart Journal</i> , 2017, 188, 127-135.	1.2	5
692	Engagement, Research, and Evidence. <i>Circulation</i> , 2017, 135, 1478-1480.	1.6	5
693	Paving a Better Path for Patients Dying of Heart Disease. <i>Circulation</i> , 2018, 137, 1216-1217.	1.6	5
694	Netâ€œclinical benefit of extended prophylaxis of venous thromboembolism with betrixaban in medically ill patients aged 80 or more. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 2089-2098.	1.9	5
695	PARAGON-HF Clinical Trial Eligibility in a Population of Patients Hospitalized With Heart Failure. <i>Journal of Cardiac Failure</i> , 2019, 25, 1009-1011.	0.7	5
696	Glycated Hemoglobin and Outcomes of Heart Failure (from Get With the Guidelines-Heart Failure). <i>American Journal of Cardiology</i> , 2019, 123, 618-626.	0.7	5
697	Impact of baseline covariate imbalance on bias in treatment effect estimation in cluster randomized trials: Race as an example. <i>Contemporary Clinical Trials</i> , 2020, 88, 105775.	0.8	5
698	Considerations for using distributed research networks to conduct aspects of randomized trials. <i>Contemporary Clinical Trials Communications</i> , 2020, 17, 100515.	0.5	5
699	A Novel In-hospital Congestion Score to Risk Stratify Patients Admitted for Worsening Heart Failure (from ASCEND-HF). <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 540-548.	1.1	5
700	Implications of peripheral oedema in heart failure with preserved ejection fraction: a heart failure network analysis. <i>ESC Heart Failure</i> , 2021, 8, 662-669.	1.4	5
701	Predicting major adverse limb events in individuals with type 2 diabetes: Insights from the EXSCEL trial. <i>Diabetic Medicine</i> , 2021, 38, e14552.	1.2	5
702	Multiparameter diagnostic sensor measurements in heart failure patients presenting with SARSâ€œCoVâ€œ2 infection. <i>ESC Heart Failure</i> , 2021, 8, 4026-4036.	1.4	5

#	ARTICLE	IF	CITATIONS
703	Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e2117963.	2.8	5
704	Association of Vasopressor Choice with Clinical and Functional Outcomes Following Moderate to Severe Traumatic Brain Injury: A TRACK-TBI Study. <i>Neurocritical Care</i> , 2022, 36, 180-191.	1.2	5
705	Identifying Treatments for Stage C2 Heart Failure. <i>JAMA Cardiology</i> , 2022, 7, 34.	3.0	5
706	Risk Factors and Neurological Outcomes Associated With Circulatory Shock After Moderate to Severe Traumatic Brain Injury: A TRACK-TBI Study. <i>Neurosurgery</i> , 2022, 91, 427-436.	0.6	5
707	Nesiritide in Acute Decompensated Heart Failure. <i>New England Journal of Medicine</i> , 2011, 365, 1547-1547.	13.9	4
708	In Reply: B-type natriuretic peptide level and postdischarge thrombotic events in older patients hospitalized with heart failure: Insights from the ADHERE registry. <i>American Heart Journal</i> , 2013, 165, e3.	1.2	4
709	Chest pain in patients with heart failure: why history may matter. <i>European Heart Journal</i> , 2014, 35, 3408-3409.	1.0	4
710	Characteristics, quality of care, and in-hospital outcomes of Asian-American heart failure patients: Findings from the American Heart Association Get With The Guidelines-Heart Failure Program. <i>International Journal of Cardiology</i> , 2015, 189, 141-147.	0.8	4
711	Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 298-307.	1.9	4
712	Within-Trial Evaluation of Medical Resources, Costs, and Quality of Life Among Patients With Type 2 Diabetes Participating in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL). <i>Diabetes Care</i> , 2020, 43, 374-381.	4.3	4
713	Expected vs Actual Outcomes of Elective Initiation of Inotropic Therapy During Heart Failure Hospitalization. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 529-536.	1.2	4
714	Plasma Volume Status and Its Association With In-Hospital and Postdischarge Outcomes in Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 297-308.	0.7	4
715	Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1101-1110.	2.2	4
716	When Are Treatment Blinding and Treatment Standardization Necessary in Real-World Clinical Trials?. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 116-121.	2.3	4
717	Effect of once-weekly exenatide on hospitalization for acute coronary syndrome or coronary revascularization in patients with type 2 diabetes mellitus. <i>American Heart Journal</i> , 2021, 239, 59-63.	1.2	4
718	Patient partnership in cardiovascular clinical trials. <i>European Heart Journal</i> , 2022, 43, 1432-1437.	1.0	4
719	Quantitative Blood Volume Analysis and Hemodynamic Measures of Vascular Compliance in Patients With Worsening Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 1469-1474.	0.7	4
720	Advancing care for acute heart failure—no time to relax. <i>Lancet</i> , 2009, 373, 1401-1402.	6.3	3

#	ARTICLE	IF	CITATIONS
721	Patterns and Predictors of Discharge Statin Prescription Among Hospitalized Patients With Intracerebral Hemorrhage. <i>Stroke</i> , 2010, 41, 2271-2277.	1.0	3
722	Efficacy and safety of nesiritide in patients with acute decompensated heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 159-169.	0.6	3
723	Design and rationale of a retrospective clinical effectiveness study of aldosterone antagonist therapy in patients with heart failure. <i>American Heart Journal</i> , 2012, 163, 946-953.e1.	1.2	3
724	DO COUNTRIES OR HOSPITALS WITH LONGER STAYS HAVE LOWER READMISSION RATES? FINDINGS FROM THE ASCEND-HF TRIAL. <i>Journal of the American College of Cardiology</i> , 2012, 59, E1029.	1.2	3
725	Preventing Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 44.	3.8	3
726	Postdischarge International Normalized Ratio Testing and Long-term Clinical Outcomes of Patients With Heart Failure Receiving Warfarin: Findings From the <sc>ADHERE</sc> Registry Linked to Medicare Claims. <i>Clinical Cardiology</i> , 2013, 36, 757-765.	0.7	3
727	Combined Use of Warfarin and Oral <sc>P2Y12</sc> Inhibitors in Patients With Atrial Fibrillation and Acute Coronary Syndrome. <i>Clinical Cardiology</i> , 2014, 37, 152-159.	0.7	3
728	ASSOCIATION BETWEEN SERUM POTASSIUM LEVEL AND OUTCOMES IN HEART FAILURE WITH REDUCED EJECTION FRACTION: A COHORT STUDY FROM THE SWEDISH HEART FAILURE REGISTRY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 678.	1.2	3
729	When Should Patients Be Involved in Cardiovascular Clinical Trial Design?. <i>JAMA Cardiology</i> , 2017, 2, 1269.	3.0	3
730	Absence of July Phenomenon in Acute Ischemic Stroke Care Quality and Outcomes. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	3
731	Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes?. <i>Circulation</i> , 2018, 138, 2787-2797.	1.6	3
732	OUTCOMES OF NON-SURGICAL PATIENTS WITH SEVERE TRICUSPID REGURGITATION AND CONGESTIVE HEART FAILURE. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1948.	1.2	3
733	Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors. <i>Stroke and Vascular Neurology</i> , 2021, 6, 384-394.	1.5	3
734	Early diuretic strategies and the association with In-hospital and Post-discharge outcomes in acute heart failure. <i>American Heart Journal</i> , 2021, 239, 110-119.	1.2	3
735	Relationship between Hospital 30-Day Mortality Rates for Heart Failure and Patterns of Early Inpatient Comfort Care. <i>Journal of Hospital Medicine</i> , 2018, 13, 170-176.	0.7	3
736	Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model. <i>ESC Heart Failure</i> , 2022, 9, 178-185.	1.4	3
737	Dysglycemia and incident heart failure among blacks: The jackson heart study. <i>American Heart Journal</i> , 2022, 245, 1-9.	1.2	3
738	Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HF. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	3

#	ARTICLE	IF	CITATIONS
739	Outcomes After Acute Coronary Syndrome in Patients With Diabetes Mellitus and Peripheral Artery Disease (from the TRACER, TRILOGY-ACS, APPRAISE-2, and PLATO Clinical Trials). <i>American Journal of Cardiology</i> , 2022, 178, 11-17.	0.7	3
740	Topical Anesthesia With EMLA Reduces Pain During Endomyocardial Biopsy: a Randomized Trial. <i>Journal of Heart and Lung Transplantation</i> , 2006, 25, 1164-1166.	0.3	2
741	Influence of the American Heart Association's Get With The Guidelines (GWTG) Program on the Quality of Care for Patients Hospitalized with Heart Failure. <i>Journal of Cardiac Failure</i> , 2006, 12, S130-S130.	0.7	2
742	Advanced Heart Failure. <i>Progress in Cardiovascular Diseases</i> , 2011, 54, 77.	1.6	2
743	Successful Organ Donation After Long-Term Circulatory Support With Nonpulsatile Mechanical Support. <i>American Journal of Transplantation</i> , 2012, 12, 1962-1963.	2.6	2
744	Prescribing warfarin at discharge for heart failure patients: Findings from the Get With The Guidelines-Heart Failure Registry. <i>International Journal of Cardiology</i> , 2014, 172, e322-e323.	0.8	2
745	Elevated Heart Rate in Patients with Heart Failure with Reduced Ejection Fraction: Associations with One-Year Survival and Costs. <i>Journal of Cardiac Failure</i> , 2015, 21, S121-S122.	0.7	2
746	Correlation between peak expiratory flow rate and NT-proBNP in patients with acute heart failure. An analysis from ASCEND-HF trial. <i>International Journal of Cardiology</i> , 2015, 182, 184-186.	0.8	2
747	Response by Hess et al to Letter Regarding Article, "Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Program". <i>Circulation</i> , 2017, 135, e22-e23.	1.6	2
748	TIMING AND CLINICAL PREDICTORS OF EARLY VERSUS LATE READMISSION AMONG PATIENTS HOSPITALIZED FOR ACUTE HEART FAILURE: INSIGHTS FROM ASCEND-HF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 766.	1.2	2
749	Response by Kumbhani et al to Letters Regarding Article, "Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure: Insights From Get With The Guidelines-Heart Failure". <i>Circulation</i> , 2018, 138, 2306-2307.	1.6	2
750	Providing Individual Research Results to Participants—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 2601.	3.8	2
751	Evolving the Hospital Readmissions Reduction Program. <i>Journal of the American College of Cardiology</i> , 2019, 74, 235-237.	1.2	2
752	Haemoconcentration during treatment of acute heart failure with cardiorenal syndrome: from the CARRESS-HF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1472-1476.	2.9	2
753	Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus. <i>Journal of the American Heart Association</i> , 2020, 9, e012405.	1.6	2
754	Data Sharing Goals for Nonprofit Funders of Clinical Trials. <i>Journal of Participatory Medicine</i> , 2021, 13, e23011.	0.7	2
755	Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial. <i>Diabetes Research and Clinical Practice</i> , 2022, 183, 109152.	1.1	2
756	The challenges of data safety monitoring for a pragmatic study: Lessons from the ADAPTABLE study. <i>Contemporary Clinical Trials</i> , 2022, 115, 106732.	0.8	2

#	ARTICLE	IF	CITATIONS
757	Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges. <i>Clinical Trials</i> , 2022, 19, 561-572.	0.7	2
758	Third and fourth heart sounds had low sensitivity but moderate to high specificity for predicting left ventricular dysfunction.. <i>Evidence-Based Medicine</i> , 2005, 10, 182-182.	0.6	1
759	A centralised telephone intervention reduced combined all cause mortality or admission for worsening HF in chronic heart failure. <i>Evidence-Based Medicine</i> , 2006, 11, 50-50.	0.6	1
760	BNP-Guided Heart Failure Therapy in Older Patients. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 2091.	3.8	1
761	Cystatin C as a Biomarker of Worsening Renal Function in Acute Heart Failure: Insights from the DOSE Study. <i>Journal of Cardiac Failure</i> , 2011, 17, S58.	0.7	1
762	Digoxin initiation is associated with lower risk of all-cause readmission after hospitalisation for heart failure. <i>Evidence-Based Medicine</i> , 2014, 19, 153-153.	0.6	1
763	PERMANENT PACEMAKER USE AND OUTCOMES IN OLDER PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION. <i>Journal of the American College of Cardiology</i> , 2014, 63, A860.	1.2	1
764	A Stepwise Pharmacological Care Algorithm for Cardiorenal Syndrome for Acute Heart Failure: Insights from DOSE-AHF, CARRESS-HF, and ROSE-AHF. <i>Journal of Cardiac Failure</i> , 2014, 20, S13.	0.7	1
765	Novel Protein Glycan Inflammatory Biomarkers Predict Adverse Events in Heart Failure with Preserved Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2015, 21, S89.	0.7	1
766	Sex Differences in the Management and Outcomes of Heart Failure with Preserved Ejection Fraction in Patients Presenting to the Emergency Department with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, S62.	0.7	1
767	Pooled RCTs: β -blockers reduce mortality in heart failure patients with sinus rhythm but not in those with AF. <i>Annals of Internal Medicine</i> , 2015, 162, JC7.	2.0	1
768	Representativeness of Medicare Participants in the Jackson Heart Study for African American Medicare Beneficiaries. <i>Epidemiology</i> , 2017, 28, 740-746.	1.2	1
769	Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy. <i>European Journal of Heart Failure</i> , 2018, 20, 1227-1229.	2.9	1
770	Characterization of Major and Clinically Relevant Non-Major Bleeds in the APEX Trial. <i>TH Open</i> , 2019, 03, e103-e108.	0.7	1
771	PATIENTS WITH DIABETES AND PERIPHERAL ARTERIAL DISEASE: RESULTS FROM THE EXSCEL TRIAL. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2040.	1.2	1
772	Does Guideline-Directed Medical Therapy for Heart Failure Offer Benefits After LVAD Placement?â€”A Call for a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2020, 5, 183.	3.0	1
773	From Theory to Practice. <i>JACC: Heart Failure</i> , 2020, 8, 55-56.	1.9	1
774	Disseminating trial results: We can have both faster and better. <i>Healthcare</i> , 2020, 8, 100474.	0.6	1

#	ARTICLE	IF	CITATIONS
775	The Use of Sacubitril/Valsartan for Hospitalized Heart Failure—Why Do We Care About Cost and Value?. <i>JAMA Cardiology</i> , 2020, 5, 1244.	3.0	1
776	Abstract 17368: Years of Life Lost Due to Heart Failure in the United States (US). <i>Circulation</i> , 2015, 132, .	1.6	1
777	Echocardiogram Utilization Patterns and Association With Mortality Following Severe Traumatic Brain Injury. <i>Anesthesia and Analgesia</i> , 2021, 132, 1060-1066.	1.1	1
778	Inverse relationship between body mass index and risk of venous thromboembolism among medically ill hospitalized patients: Observations from the APEX trial. <i>Thrombosis Research</i> , 2022, 211, 63-69.	0.8	1
779	Plasma metabolites associated with functional and clinical outcomes in heart failure with reduced ejection fraction with and without type 2 diabetes. <i>Scientific Reports</i> , 2022, 12, .	1.6	1
780	Carvedilol reduced mortality and hospital admission in severe chronic heart failure, regardless of pretreatment systolic BP. <i>Evidence-Based Medicine</i> , 2005, 10, 9-9.	0.6	0
781	Hoping for the best while preparing for the worst: Communication about end-of-life planning in Heart Transplant Programs. <i>Journal of Heart and Lung Transplantation</i> , 2005, 24, S44.	0.3	0
782	Reliability of Heart Failure Patient Care: Initial Results from the American Heart Association's Get With The Guidelines (GWTG) Heart Failure Program. <i>Journal of Cardiac Failure</i> , 2006, 12, S95-S95.	0.7	0
783	Features and Hospital Outcomes for Nonadherent Patients with Heart Failure: Findings from GWTG-HF. <i>Journal of Cardiac Failure</i> , 2008, 14, S7.	0.7	0
784	Weekend Hospital Admission for Heart Failure: Influence on Quality of Care, Length of Stay, and In-Hospital Mortality. <i>Journal of Cardiac Failure</i> , 2008, 14, S7-S8.	0.7	0
785	Translating Evidence into Practice: Use of Statins in Real-World Patients with Heart Failure. <i>Heart Failure Clinics</i> , 2008, 4, 217-223.	1.0	0
786	Sex Differences in Hospital Risk-Adjusted Mortality Rates for Medicare Beneficiaries Undergoing CABG Surgery—Invited Commentary. <i>Archives of Internal Medicine</i> , 2008, 168, 2323.	4.3	0
787	Implantable Cardioverter-Defibrillators, Heart Failure, and Patient Characteristics—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, .	3.8	0
788	Outcomes of Medicare Beneficiaries With Ventricular Assist Devices—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2009, 301, 1656.	3.8	0
789	A change of heart. <i>Journal of Hospital Medicine</i> , 2009, 4, 131-136.	0.7	0
790	Early Physician Follow-up and 30-Day Readmission Among Older Patients With Heart Failure—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 743.	3.8	0
791	Aldosterone Antagonists in Patients With Heart Failure—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 833.	3.8	0
792	141 STAGE MIGRATION IN PROSTATE CANCER AT RADICAL PROSTATECTOMY DURING THE PSA ERA IS ASSOCIATED WITH RELATIVELY CONSTANT GLEASON SCORE. <i>Journal of Urology</i> , 2010, 183, .	0.2	0

#	ARTICLE	IF	CITATIONS
793	Admission, Discharge, or Change in BNP and Long-Term Mortality: Data from OPTIMIZE-HF Linked with Medicare Claims. <i>Journal of Cardiac Failure</i> , 2010, 16, S7-S8.	0.7	0
794	Use and Predictors of Heart Failure Disease Management Referral in Patients Hospitalized With Heart Failure: Insights from the American Heart Association "Get with the Guidelines" Program. <i>Journal of Cardiac Failure</i> , 2010, 16, S78.	0.7	0
795	Characterization of Heart Failure Patients With Preserved Systolic Function: A Comparison between ADHERE-US Registry and ADHERE-International Registry. <i>Journal of Cardiac Failure</i> , 2010, 16, S79.	0.7	0
796	Venous Thromboembolism Prophylaxis among Elderly Heart Failure Patients and 60-Day Outcomes: An Analysis from ADHERE Linked to Medicare Claims. <i>Journal of Cardiac Failure</i> , 2010, 16, S92.	0.7	0
797	2008 IDENTIFICATION OF VARIABLES ASSOCIATED WITH INCREASED PAIN DURING TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY. <i>Journal of Urology</i> , 2010, 183, .	0.2	0
798	2035 FAMILY HISTORY OF PROSTATE CANCER DOES NOT INCREASE THE RISK OF DETECTION OF PROSTATE CANCER NOR HIGH GRADE DISEASE IN MEN UNDERGOING INITIAL PROSTATE BIOPSY. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
799	967 C-INDEX ASSOCIATES WITH FUNCTIONAL OUTCOMES AFTER LAPAROSCOPIC PARTIAL NEPHRECTOMY. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
800	508 Acute heart failure: Canadian perspectives from an RCT and a registry. <i>Canadian Journal of Cardiology</i> , 2011, 27, S246.	0.8	0
801	Association between VE-VCO ₂ Slope and Resting Hemodynamic Measurements in Ambulatory Heart Failure (HF) Patients: An Analysis from the Duke Advanced HF Database. <i>Journal of Cardiac Failure</i> , 2011, 17, S8-S9.	0.7	0
802	International Variation in Use of Anticoagulation among Heart Failure Patients with Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , 2011, 17, S72.	0.7	0
803	Review: Cardiac resynchronization reduces mortality and hospitalizations in patients with either more or less symptomatic HF. <i>Annals of Internal Medicine</i> , 2011, 155, JC2.	2.0	0
804	Addressing the 100% of Heart Failure: A Call for Complete Care of All Ages. <i>Circulation: Heart Failure</i> , 2012, 5, 667-668.	1.6	0
805	Response to Letter Regarding Article, "Mechanisms of Bleeding and Approach to Patients With Axial-Flow Left Ventricular Assist Devices". <i>Circulation: Heart Failure</i> , 2012, 5, .	1.6	0
806	1114 ROBOTIC PARTIAL NEPHRECTOMY VERSUS LAPAROSCOPIC CRYOABLATION FOR THE SMALL RENAL MASS. <i>Journal of Urology</i> , 2012, 187, .	0.2	0
807	130 Extended Criteria Cardiac Transplantation Versus Destination Therapy Left Ventricular Assist Device Therapy in the Continuous Flow Era. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, S52-S53.	0.3	0
808	Early International Normalized Ratio (INR) Monitoring and Long-Term Clinical Outcomes in Warfarin Users with Heart Failure: Findings from ADHERE Linked with Medicare Claims. <i>Journal of Cardiac Failure</i> , 2012, 18, S92.	0.7	0
809	Admission Heart Rate and In-Hospital Outcomes in Patients Hospitalized for Heart Failure in Sinus Rhythm and Atrial Fibrillation. <i>Journal of Cardiac Failure</i> , 2012, 18, S73-S74.	0.7	0
810	Do BNP Levels and Prognostic Value Vary by Race/Ethnicity in Patients Hospitalized With Heart Failure?. <i>Journal of Cardiac Failure</i> , 2012, 18, S80-S81.	0.7	0

#	ARTICLE	IF	CITATIONS
811	819 Does a Low Ejection Fraction Predict Mortality? Insights From the ASCEND-HF Trial. Canadian Journal of Cardiology, 2012, 28, S413-S414.	0.8	0
812	Does Atrial Fibrillation Affect Outcomes in Patients Admitted With Acute Heart Failure? Insights From the Ascend-Hf Trial. Canadian Journal of Cardiology, 2013, 29, S147-S148.	0.8	0
813	Generalizability of RELAX-AHF Clinical Trial Patients to a Large US Registry. Journal of Cardiac Failure, 2013, 19, S27.	0.7	0
814	Nesiritide Administration in Patients Hospitalized for Acute Decompensated Heart Failure: Does Timing Matter?. Journal of Cardiac Failure, 2013, 19, S66.	0.7	0
815	IVC Filters and Postoperative Outcomes in Patients Undergoing Bariatric Surgery: A Meta-analysis. Chest, 2013, 144, 849A.	0.4	0
816	Authors' Reply. Clinical Cardiology, 2014, 37, 323-323.	0.7	0
817	Transient and Persistent Worsening Renal Function during Acute Heart Failure Hospitalization: Insights from the ADHERE Registry Linked to Medicare Claims. Journal of Cardiac Failure, 2014, 20, S14.	0.7	0
818	Differential Response to Low Dose Dopamine or Nesiritide in Patients with Acute Heart Failure and Renal Dysfunction in Accordance to LV EF: Sub-Group Analysis of the ROSE AHF Trial. Journal of Cardiac Failure, 2014, 20, S94.	0.7	0
819	Clinical Characteristics and Outcomes of Patients with Discordant Findings at Right Heart Catheterization and Cardiopulmonary Exercise Testing. Journal of Cardiac Failure, 2014, 20, S49-S50.	0.7	0
820	In heart failure, automatic implant-based telemonitoring reduced a composite of cardiac events and mortality. Annals of Internal Medicine, 2014, 161, JC10.	2.0	0
821	Cardiac Transplantation for Older Patients: Characteristics and Outcomes in the Septuagenarian Population. Journal of Cardiac Failure, 2015, 21, S9.	0.7	0
822	Elevated Total Bilirubin on Admission is a Marker of Worse 30- and 180-Day Outcomes for Patients With Acute HF: Insights From ASCEND-HF. Journal of Cardiac Failure, 2015, 21, S120-S121.	0.7	0
823	Temporal Trends of Digoxin Use in Patients Hospitalized with Heart Failure: Analysis From the American Heart Association Get With The Guidelines - Heart Failure Registry. Journal of Cardiac Failure, 2015, 21, S62.	0.7	0
824	Trends and Outcomes of Patients with Adult Congenital Heart Disease With Pulmonary Hypertension Listed for Orthotopic Heart Transplantation in the United Network for Organ Sharing Database. Journal of Cardiac Failure, 2015, 21, S8.	0.7	0
825	The Clinical Implications of Cardiac Troponin I Measured by an "Ultra-sensitive" Assay in Acute Decompensated Heart Failure: Insights from ASCEND-HF. Journal of Cardiac Failure, 2015, 21, S25-S26.	0.7	0
826	Trends in the Use of Guideline-based Therapies Among Dialysis Patients Hospitalized with Heart Failure: Findings from Get With The Guidelines-Heart Failure. Journal of Cardiac Failure, 2015, 21, S114-S115.	0.7	0
827	Measuring heart failure quality: does perfection matter?. Heart, 2015, 101, 1691-1692.	1.2	0
828	What's Harder: Seeing a Doctor or Reducing Readmissions? —. JACC: Heart Failure, 2015, 3, 774-776.	1.9	0

#	ARTICLE	IF	CITATIONS
829	Response to Letter Regarding Article, "Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women". <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	0
830	Insufficient Reduction in Heart Rate during Hospitalization Despite Beta-Blocker Treatment in Acute Decompensated Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, S100-S101.	0.7	0
831	Laboratory Monitoring after Inpatient and Outpatient Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients with Heart Failure. <i>Journal of Cardiac Failure</i> , 2016, 22, S26.	0.7	0
832	Regional Differences during Acute Heart Failure Hospitalizations of Patients with Heart Failure with Preserved Ejection Fraction: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2016, 22, S27.	0.7	0
833	Response to Letter Regarding Article, "Temporal Trends and Variation in Early Scheduled Follow-up After a Hospitalization for Heart Failure: Findings from Get With The Guidelines-Heart Failure." <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	0
834	HEMOCONCENTRATION DURING MANAGEMENT OF PATIENTS WITH ACUTE HEART FAILURE AND CARDIORENAL SYNDROME: INSIGHTS FROM CARRESS-HF. <i>Journal of the American College of Cardiology</i> , 2017, 69, 767.	1.2	0
835	THE IMPACT OF THE CURRENT VERSUS PRIOR CARDIAC RESYNCHRONIZATION GUIDELINES ON THE PROPORTION OF HOSPITALIZED HEART FAILURE PATIENTS ELIGIBLE FOR THERAPY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 784.	1.2	0
836	A HOSPITAL LEVEL ANALYSIS OF 30-DAY READMISSION RATES FOR HEART FAILURE PATIENTS AND LONG-TERM SURVIVAL AMONG HIGHEST AND LOWEST PERFORMING HOSPITALS, FINDINGS FROM GET WITH THE GUIDELINES-HEART FAILURE. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2565.	1.2	0
837	Integrating Research With Clinical Practice. <i>JAMA Cardiology</i> , 2017, 2, 616.	3.0	0
838	Making Every Mobile Heart Count!. <i>JAMA Cardiology</i> , 2017, 2, 78.	3.0	0
839	The Burden of Non-Cardiac Comorbidities in Acute Heart Failure: Insights From ASCEND-HF. <i>Journal of Cardiac Failure</i> , 2017, 23, S109.	0.7	0
840	Improving heart failure health: is there a secret Swedish sauce?. <i>European Journal of Heart Failure</i> , 2017, 19, 1117-1118.	2.9	0
841	Periprocedural Risk and Survival after ICD Placement in Patients with Advanced Heart Failure. <i>Journal of Cardiac Failure</i> , 2018, 24, S63.	0.7	0
842	Improvements in Health Status Associated with Medication Adjustments in Outpatients with HFrEF: Insights from the CHAMP-HF Registry. <i>Journal of Cardiac Failure</i> , 2018, 24, S102-S103.	0.7	0
843	Diabetes is Associated with Worse In-Hospital and 30-Day Post-Discharge Morbidity in Patients with Heart Failure with Preserved Ejection Fraction: Findings from the Get With The Guidelines Heart Failure Registry. <i>Journal of Cardiac Failure</i> , 2018, 24, S92.	0.7	0
844	Association between Sacubitril/Valsartan Initiation and Health Status Outcomes in Heart Failure with Reduced Ejection Fraction: Findings from the CHAMP-HF Registry. <i>Journal of Cardiac Failure</i> , 2018, 24, S9.	0.7	0
845	Use of Target Doses of Guideline Directed Medical Therapy in Heart Failure by Systolic Blood Pressure: Insights from the CHAMP-HF Registry. <i>Journal of Cardiac Failure</i> , 2018, 24, S71.	0.7	0
846	Patient and Practice Characteristics Associated with Sacubitril/Valsartan Use in the United States. <i>Journal of Cardiac Failure</i> , 2018, 24, S98-S99.	0.7	0

#	ARTICLE	IF	CITATIONS
847	Review: In noncardiac surgery, amiodarone, β -blocker, or statin prophylaxis reduces postoperative AF. <i>Annals of Internal Medicine</i> , 2018, 169, JC7.	2.0	0
848	The Call for Precision Health Trials in Older Adults. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2537-2539.	1.2	0
849	Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized with Heart Failure. <i>Journal of Cardiac Failure</i> , 2019, 25, S151.	0.7	0
850	What Is Needed Now to Improve Cardiovascular Clinical Registries in the Future. <i>JAMA Cardiology</i> , 2019, 4, 201.	3.0	0
851	Reply. <i>JACC: Heart Failure</i> , 2019, 7, 85.	1.9	0
852	Statistical Code for Clinical Research Papers. <i>Annals of Internal Medicine</i> , 2019, 170, 80.	2.0	0
853	Quality and Outcomes in Heart Failure. , 2020, , 697-704.e2.		0
854	Effect Of Vericiguat In Victoria According To Guideline-directed Medical Therapy. <i>Journal of Cardiac Failure</i> , 2020, 26, 1108-1109.	0.7	0
855	Leveraging "Big Data" for the Design and Execution of Clinical Trials. , 2021, , 1-23.		0
856	Obstructive Sleep Apnea and Postoperative Outcome. <i>Chest</i> , 2011, 140, 342A.	0.4	0
857	Afternoon Adenoma Detection Rate in Half Day Blocks vs. All Day Procedures: Is There a Difference?. <i>American Journal of Gastroenterology</i> , 2011, 106, S563-S564.	0.2	0
858	Abstract MP28: Heart Rate At Hospital Discharge Is Associated With Adverse Long Term Outcomes In Patients With Heart Failure. <i>Circulation</i> , 2014, 129, .	1.6	0
859	Abstract 15556: Effects of Left Ventricular Assist Device Support on microRNA Levels. <i>Circulation</i> , 2014, 130, .	1.6	0
860	Abstract 17304: Sudden Cardiac Death After Acute Heart Failure Hospitalization: Insights From ASCEND-HF. <i>Circulation</i> , 2015, 132, .	1.6	0
861	The Safety and Efficacy of Full Versus Reduced Dose Betrixaban in the Acute Medically Ill VTE (Venous) Tj ETQq1 1 0.784314 rgBT /Over 3824-3824.	0.6	0
862	EXSCEL "Once-Weekly Exenatide Reduces Medical Resource Utilization in Patients with Type 2 Diabetes Mellitus. <i>Diabetes</i> , 2018, 67, 1319-P.	0.3	0
863	Impact of SGLT2 Inhibitors (SGLT2i) on Cardiovascular (CV) Risk and Estimated Glomerular Filtration Rate (eGFR) in the EXSCEL Placebo Group. <i>Diabetes</i> , 2018, 67, 130-LB.	0.3	0
864	Anticoagulation and Clinical Outcomes in Heart Failure Patients With Atrial Fibrillation: Findings From the ADHERE Registry. <i>Journal of Atrial Fibrillation</i> , 2013, 6, 953.	0.5	0

#	ARTICLE	IF	CITATIONS
865	A Hospital and Postdischarge Quality Improvement Intervention and Outcomes and Care for Patients With Heart Failure With Reduced Ejection Fractionâ€”Reply. JAMA - Journal of the American Medical Association, 2021, 326, 1977.	3.8	0
866	Abstract 13829: Index Event, Clinical Outcomes and Response to Vericiguat in the Victoria Trial. Circulation, 2020, 142, .	1.6	0
867	Abstract 17114: Whose Work is It? Patient Perspectives on Challenges in Heart Failure Self-Management. Circulation, 2020, 142, .	1.6	0
868	Abstract 12817: Comparison of New York Heart Association Classification and Patient-reported Outcomes Among Heart Failure Patients in U.S. Clinical Practice: CHAMP-HF. Circulation, 2020, 142, .	1.6	0
869	Poor Medication Adherence Is Associated With Worse Health Status In Heart Failure With Reduced Ejection Fraction. Journal of Cardiac Failure, 2022, 28, S119.	0.7	0
870	Review: Implantable cardioverter defibrillators reduce all-cause mortality in nonischemic cardiomyopathy. ACP Journal Club, 2005, 142, 57.	0.1	0
871	Abstract P92: Racial Differences in End of Life Care in Medicare Beneficiaries With Heart Failure. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, .	0.9	0